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ABSTACT
Terrence Dairon Lewis: MECHANISMS OF ESTROGEN SENSITIVITY IN THE HUMAN
ENDOMETRIUM
(Under the direction of David G. Kaufman, MD, PhD)
Endometrial cancer is the most common gynecologic malignancy, and a major cause
of morbidity and mortality in women in the Western World. The American Cancer Society
estimates that 41,200 cases will be diagnosed and 7,350 deaths will result from endometrial
cancer in the United States in 2007. Unopposed estrogen exposure is the primary etiologic
risk factor for developing this disease. However, the effects of estrogen and its receptors are
not well defined within the human endometrium. The principal goal of this dissertation was
to understand the individual contributions of the estrogen receptors (ERs)  and  within
epithelial cells of the endometrium. To this end, three specific aims were developed to help
further our understanding of the functions of these receptors in this tissue: (1) evaluate the
expression of the receptors in normal, hyperplastic, and malignant tissue, (2) evaluate the
effects of the receptor subtypes on the estrogen-inducible placental alkaline phosaphatase
(ALPP) gene, and (3) to evaluate the effects of the receptors on proliferation of endometrial
adenocarcinoma cells. Findings from the first aim indicate that an alteration in the normal
ER/ER ratio takes place in the stromal and epithelial compartments of the endometrium at
the pre-malignant (hyperplastic) state. We believe that this change may be a key step that
permits the endometrium to produce an exaggerated response to estrogens. Further studies
evaluating the effects of the receptors on the ALPP gene used highly specific agonists of the
iv
estrogen receptors, PPT and DPN, along with cell lines expressing one receptor or the other.
These studies reveal that ER, and not ER, is responsible for the upregulation of ALPP.
Further studies utilizing inhibitors of both MAP-Kinase and (PI)3-Kinase, revealed that the
upregulation of ALPP is at least in part due to these signaling pathways within this model
system. In our final aim we learned that ER, and not ER, is involved in estrogen-induced
proliferation of endometrial epithelial cells. Furthermore, ER acts as an inhibitor of
proliferation within this tissue by possibly inhibiting the cell cycle by regulating key
components of the cell cycle machinery.
vThis dissertation is dedicated to all those, past and present, who fought and continue to fight
for equality and civil rights.
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Chapter I: Introduction
Uterine biology
Ontogeny of the uterus
During early embryogenesis, both males and females have undifferentiated gonads
and have mesodermally derived Wolffian and Mullerian ducts. Wolffian ducts can develop
into the male internal genitalia including the epididymus, seminal vesicles, and vas deferens.
On the other hand, Mullerian ducts form the luminal and glandular epithelium of the uterus,
in addition to the epithelial lining of the oviduct, cervix and upper vagina. Each Mullerian
duct is surrounded by urogenital ridge mesenchyme that gives rise to the fibromuscular wall
of the uterus, endometrial stroma and myometrium (Wynn and Jollie 1989). Additionally,
this layer gives rise to the connective tissue and muscle layers of the oviduct, cervix, and
upper vagina. Genetic information carried on the Y chromosome of XY embryos leads to the
development of testes, which cause male internal and external genitalia to develop by
producing testosterone and Mullerian Inhibiting Factor (MIF) (Gilbert 1997). In the absence
of a Y chromosome, Mullerian duct development occurs by default and female internal
genitalia result. The female external genitalia including the labia and clitoris are also the
default. However, the external genitalia are not derived from the Mullerian ducts.
2Figure 1.1. The Female Reproductive Organs
***Used with permission from Web MD***
3Basic uterine anatomy
The female reproductive tract consists of the vagina, cervix (cervix uteri), uterus
(corpus urteri), fallopian tubes, and ovaries. At the upper portion of the uterus the fallopian
tubes and oviducts open, bilaterally, and extend outward to surround the ovaries. The cavity
of the uterus is connected with the vagina directly via the cervical canal, which is located
directly below the uterus and within by the cervix. The uterus of an adult woman who has not
previously had children measures about 7.5 cm in length, 5 cm in breadth, at its upper part,
and nearly 2.5 cm in thickness, weighing roughly 30 to 40 grams (Beckmann 2002). The
uterus is a pear-shaped, thick-walled, muscular, hollow organ situated within the pelvic
cavity between the bladder and rectum. The slight constriction between the apex and base
which give the uterus its pear shape is known as the isthmus. The portion above the isthmus
is termed the body and that below is the cervix. The biological role of this organ is to receive
the blastocyst into its endometrial lining, nourish the developing blastocyst, and ultimately
discharge the fetus at birth (Wynn and Jollie 1989). During pregnancy the uterus undergoes
changes in size and structure to accommodate the needs of the developing embryo. Following
birth the uterus returns to approximately its original size, but, typically remains somewhat
enlarged.
The uterus can be divided into several structures including the body (corpus uteri), the
cervix and cervical canal (cervical uteri), the endometrium, the myometrium, and the
peritoneum. Most of the uterus is comprised of the corpus uteri, which makes up the top
portion of the pear-shaped organ. The convex portion of the uterus in which the fallopian
tubes are attached is known as the fundus. Below the isthmus, the uterus becomes conical in
shape and terminates at the cervix. The cervical canal enters the vaginal canal providing
4direct linkage between the uterus and the vagina. The uterus is comprised of three layers: the
endometrium is the innermost lining of the organ. The myometrium, the middle layer, is a
thick layer consisting of smooth muscle and the blood vessels that serve the organ. Finally,
like abdominal organs, the uterus is covered by the peritoneum, a serous membrane
composed of a layer of mesothelium and a thin layer of connective tissue.
The endometrium
As shown in Figure 1.1, the endometrium is the inner lining of the uterus, covering
the uterine cavity. The endometrium contains two distinct layers, the basalis and the
functionalis (Figure 1.2). The basalis directly contacts the myometrium and undergoes
comparatively minor changes throughout the menstrual cycle. The functionalis, which is
divided into the stratum compactum and stratum spongiosum, surrounds the lumen of the
uterine cavity and undergoes extensive remodeling during the menstrual cycle. The
functionalis of the endometrium consists of two distinct cell types: epithelial cells, which
form the luminal surface and endometrial glands, and the surrounding stromal cells (Ludwig
and Spornitz 1991).
The luminal epithelium is the internal lining of the endometrial cavity and is the
internal site of contact between the implanting blastocyst and the maternal organ. The
luminal layer contains cells with apical ciliation in addition to cells that lack ciliation.
Ciliated cells increase from 1:30 to 1:15 during the early to late proliferative phase of the
menstrual cycle before decreasing after day 20 to a final ratio of 1:50 (Glasser 2002; Wynn
and Jollie 1989).
5The glandular epithelium changes profoundly throughout the menstrual cycle. During
the proliferative phase, estrogen increases glandular cell proliferation leading to an increase
in the number of glandular structures. Additionally, the glandular cells have a poorly
developed secretory apparatus including the Golgi apparatus, the smooth endoplasmic
reticulum, and secretory vesicles. During the late proliferative phase the glands contain
pseudostratified columnar cells. There are few mitotic cells but now cells have developed an
elaborate secretory apparatus. As ovulation approaches there is an accumulation of glycogen
in the cytoplasm of the glandular cells. During the early secretory phase the glandular
epithelial cells transform into highly polarized cells actively involved in the production and
secretion of complex secretory products at the apical surface (Glasser 2002). Additionally,
there is a continuation of cytoplasmic glycogen deposition within the cell.
The endometrial stromal cells, also known as reticular cells, reside within the
connective tissue along with granulated stromal cells and lymphocytes. The remaining
connective tissue consists of an extracellular matrix with fibers and a gel-like polysaccharide
ground substance. During the early proliferative phase the stromal cells resemble
undifferentiated fibroblasts with mesenchymal characteristics. Through progression of the
proliferative phase, stromal cells begin to take on the characteristics attributed to fibroblasts
and begin to produce most of the matrix components (Wynn and Jollie 1989). Throughout
the menstrual cycle, stromal cells remodel the matrix in response to various factors, including
steroid hormones.
6Figure 1.2. Normal Endometrial Histology. The endometrium contains two distinct regions
termed the basalis (B) and the functionalis. The basalis resides above the myometrium (M), or
smooth muscle layer of the uterus. The functionalis, or functional layer, is made up of the
stratum compactum (C) and stratum spongiosum (S), which contains luminal and glandular
epithelium, in addition to stromal cells.
***Image used with permission from Dr. Ruth A. Lininger***
7Endometrial vasculature
The endometrial blood supply is provided by a sophisticated network of vessels that
undergo cycles of growth and regression during each menstrual cycle (Rogers 1996a). As
shown in Figure 1.3, the uterine and ovarian arteries emanate from the myometrium and form
the arcuate arteries, which give rise to the radial arteries. After passing through the junction
between the myometrium and endometrium, the radial arteries branch into the basal and
spiral arteries. As the name suggests, the basal arteries supply the basal layer while the spiral
arteries supply the functional layer. The distinctive coiled appearance of the spiral arteries
becomes more pronounced during the second half of the menstrual cycle known as the
secretory phase (Rogers 1996b).
The basal layer and its vasculature remain relatively constant throughout the
menstrual cycle. In contrast, the functional layer and its associated spiral artery vasculature
continually change under the influence of circulating steroid hormones. Despite constant
change within the functional layer, new vessel growth or angiogenesis is a tightly regulated
process in the endometrium demonstrated by the fact that vascular density remains constant
throughout the menstrual cycle (Rogers, et al. 1993). Angiogenesis is recognized to be an
essential mechanism for tumor growth, invasion, and metastatic spread. Evidence gathered
from endometrial cancer biopsies show an increase in the mean vessel density (MVD)
compared to normal endometrial biopsies (de Gois Speck, et al. 2005; Puisoru, et al. 2006;
Ribatti, et al. 2005; Stefansson, et al. 2006). This increase in vessel formation suggests that
the vasculature in the endometrium may be critical to tumor development and progression in
this complex tissue.
8Figure 1.3. Schematic Drawing of the Endometrial Vasculature.
9Ovarian control and the menstrual cycle
The menstrual cycle serves to prepare the endometrium for implantation of a
fertilized ovum. In the absence of implantation, the cycle culminates with the shedding of the
endometrial lining from the uterus. The steroid hormone estrogen plays an important role in
the development of the female reproductive tract, pregnancy, and the menstrual cycle by
providing a mitogenic stimulus. Progesterone, another steroid hormone, is also involved in
the hormonal regulation of the menstrual cycle and pregnancy, but with effects that typically
counteract the mitogenic effects of estrogen, leading to differentiation. The menstrual cycle
stage can be distinguished by changes in both the ovary and endometrium.
The menstrual cycle is regulated primarily through the hypothalamus and anterior
pituitary, which regulate the secretion of estrogen and progesterone from the follicular cells
or the corpus luteum of the ovary. The hypothalamus releases Gonadotropin Releasing
Hormone (GnRH) which stimulates the anterior pituitary to secrete Follicular Stimulating
Hormone (FSH) or Lutenizing Hormone (LH). In turn, FSH and LH stimulate the secretion
of estrogen and progesterone either by follicular cells or the corpus luteum.
Under the influence of FSH, the ovarian follicular cells develop and secrete estrogen
during the follicular phase of the menstrual cycle. The gradual increase in estrogen in the
follicular phase stimulates increased LH secretion from the anterior pituitary leading to
ovulation. Following ovulation, LH induces the follicle to become the corpus luteum, (luteal
phase) which will in turn secrete estrogen and progesterone during the second phase of the
cycle. If pregnancy does not occur, the high levels of estrogen and progesterone provide
constitutive feedback to inhibit secretion of GnRH, FSH, and LH. When LH levels decrease,
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the corpus luetum regresses and fails to secrete estrogen or progesterone, leading to
menstruation.
Endometrial changes during the menstrual cycle
For the endometrium, the menstrual cycle can be divided into the proliferative,
secretory, and menstrual phases, which reflect this tissue’s response to steroid hormones
(Glasser 2002). During a normal cycle, ovarian follicles produce estrogen, and both estrogen
and progesterone are produced by the corpus luteum, a small body formed by the follicular
cells remaining in the ovary following ovulation. Estrogen and progesterone are not secreted
at constant levels during the menstrual cycle. Instead, variations of the levels of the two
hormones, estrogen and progesterone, are observed. These changes are directly responsible
for alterations in the morphology and function of the endometrium during the menstrual
cycle. Moreover, the expression of endometrial estrogen and progesterone receptor proteins
are programmed in response to hormones throughout the cycle (Lessey, et al. 1988).
The proliferative phase, which follows menstration, is regulated by estrogen produced
by ovarian follicles. During menstration, the upper two thirds of the endometrium are shed
leaving the surface of the endometrium covered with epithelial cells proliferating from the
basal glands (Glasser 2002). As the proliferative phase ensues, the endometrium becomes
richly supplied with blood vessels that nourish the expanding tissue. Following ovulation, at
approximately the mid-point of the menstrual cycle, the secretory phase begins as estrogen
and progesterone are produced by the corpus luteum. Under the influence of the combination
of steroid hormones there is an increase in the secretory differentiation of the endometrium,
including the accumulation of glycogen and lipids within the glandular structures. If
11
Figure 1.4. Schematic Representation of the Human Menstrual Cycle. The
schematic shows both ovarian (top) and endometrial (bottom) changes throughout the
normal human menstrual cycle. Hormones that are responsible for these changes are
Follicular Stimulating Hormone (FSH), Lutenizing Hormone (LH), 17-Estradiol
(estrogen), and Progesterone.
***Image used with permission from Web MD***
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implantation occurs, human chorionic gonadotropin (hCG) is secreted by the developing
placenta which maintains estrogen and progesterone secretion by the corpus luteum
(Beckmann 2002). In the absence of implantation, the secretion of estrogen and progesterone
dramatically decreases due to luteolysis, or cyclical regression of the corpus luteum. The
spiral arteries that have grown into the endometrium contract and the upper endometrial
lining, starved of its blood supply, dies and is shed from the uterus producing the bleeding
associated with the menstrual phase. The cycle is then set to begin the proliferative phase and
the rest of the cycle once again, continuing at approximately twenty-eight day intervals from
adolescence to menopause.
Growth disorders of the endometrium: hyperplasia to neoplasia
Hyperplasia
Endometrial hyperplasia is defined as an overgrowth of both endometrial glands and
stroma, and is characterized by a proliferative glandular pattern with or without different
degrees of morphologic abnormality, or atypia (Mutter 2000). Proliferative patterns lacking
cytologic atypia are classified as hyperplasia, while those displaying atypia are deemed
atypical hyperplasia. Classification of both forms of hyperplasia can be elaborated by
assessing the degree of architectural abnormalities. Hyperplasia and atypical hyperplasia
lacking glandular complexity and crowding are designated simple hyperplasia and atypical
hyperplasia, respectively. Hyperplasia and atypical hyperplasia with increased glandular
complexity and crowding of the glands are called complex hyperplasia and complex atypical
hyperplasia, respectively.
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Increased estrogen levels, as found in polycystic ovarian syndrome (PCOS), estrogen-
secreting ovarian tumors and obesity seem to increase the occurrence of hyperplasia
(Montgomery, et al. 2004). The latter is particularly disturbing as the incidence of obesity in
the United States is increasing. Atypical hyperplasia can be treated with either progestin’s, to
counteract the effects of estrogen, or hysterectomy (Jadoul and Donnez 2003). Without
treatment, twenty-five percent of patients with atypical hyperplasia will develop endometrial
cancer (Kurman, et al. 1985).
Neoplasia
Endometrial cancer is a major cause of morbidity and mortality in women and is the
most common gynecologic malignancy of the female genital tract in the United States. The
American Cancer Society estimates that 41,200 new cases will be diagnosed and 7,350
deaths will result from endometrial cancer in the United States in 2007. The incidence of
endometrial cancer, like most cancers, is dependent on age. The median age of patients
diagnosed with this disease is 63 years. Seventy-five percent of women diagnosed with
endometrial cancer are post-menopausal.
Endometrial cancers are grouped into two broad categories. The most common
endometrial cancers are known as type-1 or glandular endometrioid. Many are estrogen
sensitive, low stage, and have an excellent prognosis. On the other hand, type-2 or serous-
papillary carcinomas, which make up ten percent of endometrial cancers, commonly are
estrogen insensitive, have a high stage when diagnosed, and carry a less favorable prognosis.
Approximately eighty percent of all type-1 endometrial cancers are of the endometrioid type.
Endometrioid lesions are classified as low or high grade by low-magnification assessment of
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the amount of solid growth, the pattern of invasion, and the presence of tumor necrosis
(Rubin and Farber 1999). Tumors are considered high grade if at least two of the following
three criteria are met: more than fifty percent solid growth, diffusely infiltrative growth, and
tumor cell necrosis.
As shown in Table 1.1 endometrial cancers are classified into several categories
based on histopathology using guidelines presented by the World Health Organization
(WHO) and the International Federation of Gynecology and Obstetrics (FIGO). The
endometrioid cancers are those mentioned as type 1 cancer above and the type 2 cancers are
the non-endometrioid cancers, particularly the papillary serous adenocarcinomas.
Unopposed stimulation of the endometrium by endogenous or exogenous estrogens is
the classic etiological factor associated with the development of endometrial carcinoma
(Rose 1996). Stimulation of the endometrium with unopposed estrogens leads to hyperplasia,
which increases the chance of development of atypical hyperplasia, and eventually type-1
endometrial cancer (Montgomery et al. 2004). Other risk factors for the development of this
disease include estrogen-secreting ovarian tumors, Polycystic Ovarian Syndrome (PCOS),
obesity, and diabetes mellitus. Each aforementioned factor is strongly associated with an
increase in unopposed estrogens (Akhmedkhanov, et al. 2001; Glasser 2002; Hale, et al.
2002). Despite this knowledge, the molecular pathogenesis of endometrial cancer not clearly
understood.
In addition to environmental factors in the development of endometrial cancer, there
is now considerable evidence for certain genetic predispositions for the disease. Patients with
Cowden’s syndrome, an autosomal dominant trait with incomplete penetrance and variable
expressivity, are characterized by germline mutations in the PTEN (phosphatase and tensin
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Table 1.1. FIGO Guidelines
Histopathologic classification
Endometrioid carcinoma
- Adenocarinoma
- Adenocanthoma
- Adenosquamous carcinoma
Non-endometrioid carcinoma
- Mucinous adenocarcinoma
- Papillary serous adenocarcinoma
- Clear-cell carcinoma
- Adenosquamous carcinoma
- Undifferentiated carcinoma
- Mixed carcinoma
Histological grade (G)
GX Grade cannot be assessed
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly or undifferentiated
Surgical staging (Stage)
1A Tumor is limited to the endometrium
1B Invasion to less than half of the myometrium
1C Invasion equal to or more than half of the endometrium
2A Endocervical glandular involvement only
2B Cervical stromal invasion
3A Invasion of serosa of the corpus uteri and /or adnexa and/or positive cytology
3B Vaginal metastasis
3C Metastases to pelvic and/or para-aortic lymph nodes
4A Tumor invasion of bladder and/or bowel mucosa
4B Distant metastasis, including intra-abdominal metastases and/or inguinal lymph
nodes
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homolog deleted on chromosome ten) tumor suppressor gene (Scheper, et al. 2006) (Kato, et
al. 2001; Ramaswamy, et al. 1999). These patients are at a considerably higher risk of
developing various cancers, including type-1 endometrial cancers, than the general
population. At the molecular level, the most common abnormality associated with type-1
endometrial cancer is the mutation of the PTEN tumor suppressor gene, which occurs in
approximately 80% of type 1 endometrial cancers (Eng 2003). The tumor suppressive
activity of PTEN is a result of its ability to negatively regulate the phosphatidylinositiol
(PI)3-kinase pathway. When receptor tyrosine kinases bind to their cognate ligands, their
intracellular tyrosine kinase domain becomes activated, leading to autophosphorylation of
certain tyrosines and recruitment of proteins with affinity for phosphotyrosine residues.
(PI)3-kinase, through its p85 regulatory subunit, is translocated from the cytosol to the
activated receptor tyrosine kinases and the activated (PI)3-kinase phosphorylates its main
substrate phosphatidylinositol-4,5 bisphosphate (PIP2) to phosphatidylinositol-3,4,5
triphosphate (PIP3) at the D3 position of the inositol ring. Accumulation of PIP3 leads to
activation of downstream kinases such as the serine/threonine kinase Akt, which mediates
cell survival and proliferation signals. PTEN was first thought to be a protein phosphatase,
but was later shown to be a lipid phosphatase whose preferred in vivo substrate is PIP3
(Maehama and Dixon 1998). The dephosphorylation of PIP3 to PIP2 by PTEN is the basis for
its ability to negatively regulate the (PI)3-kinase pathway. Loss of PTEN expression is very
common in a broad spectrum of human tumors and PTEN is among the most frequently
mutated tumor suppressor gene in human tumors, perhaps only second to p53 (Ali, et al.
1999). The loss of PTEN results in constitutive activation of the (PI)3-kinase pathway and
thus Akt, which induces cellular proliferation and decreased apoptosis (Madrid, et al. 2000;
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Figure 1.5. Abnormal Endometrial Histology. a) Normal proliferative phase showing normal
tubular glands. b) Normal secretory phase with black arrow indicating a coiled gland, which is
typical of this stage. c) Complex hyperplasia showing a single gland with complex architecture.
d) Atypical hyperplasia showing nuclei with vesciculation, chromatin clearing. e)
Adenocarcinoma reveals complex architecture and inflammatory cells in the lumen. f)
Adenosquamous carcinoma reveals several malignant glands with inflammatory cells in the
lumen. Blue arrow indicates a keratin pearl.
***Images used with permission from Pathweb of the University of Conneticut***
a. b.
c. d.
e. f.
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Myers, et al. 1998). PTEN is often lost in premalignant stages of endometrial carcinogenesis,
suggesting that loss of PTEN is an important initiator of endometrial carcinogenesis (Mutter
2002; Mutter, et al. 2000; Ruhul Quddus, et al. 2002; Stoica, et al. 2003).
Mutations in the breast cancer susceptibility gene (BRCA1) have been associated
with an increased risk for the development of endometrial cancer. In Thompson et al.’s
cohort study (2002), it was found that women carrying a mutation in BRCA1 had a two-fold
increased risk of developing endometrial cancer over the general population (Thompson and
Easton 2002). Besides PTEN and BRCA1, other genetic factors for development of type-1
cancers include, but are not limited to, the KRAS2 oncogene, and germline mutations in
DNA mismatch repair genes linked to hereditary non-polyposis colorectal cancers (HNPCC)
(Enomoto, et al. 1993; Enomoto, et al. 1991; Lax, et al. 2000). Type-2 lesions are associated
with mutations in TP53 and ERBB-2 (HER-2/neu) expression, and most are non-diploid
(Okamoto, et al. 1991; Santin 2003).
Early studies on the uterotrophic effects of estrogen and the discovery of the
estrogen receptor
The identification of estrogenic activity mediated by the ovary dates back to 1923 in
the studies of Allen and Doisy, who induced estrus in female rats by injecting them with
purified ovarian follicular extracts (Allen and Doisy 1983). Introduction of the purified
exogenous extracts into spayed rats induced growth in mammary glands, and thickening and
cornification of the vaginal walls. Further studies revealed that stimulation of the uterus with
estrogens increased the synthesis of DNA, RNA, and proteins (Gorski, et al. 1965; Kaye, et
al. 1971). Additionally, estrogen was shown to increase mitosis in the rat uterus (Kirkland, et
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al. 1979). Subsequently, the mitogenic effects of estrogen were shown to be mediated
through the induction of proto-oncogenes such as c-fos, c-jun, jun-B and jun-D, which act as
transcription factors and stimulate gene expression through AP-1 DNA elements (Chiappetta,
et al. 1992; Cicatiello, et al. 1992; Loose-Mitchell, et al. 1988; Nephew, et al. 1993a;
Nephew, et al. 1993b; Webb, et al. 1990, 1993; Weisz and Bresciani 1988; Weisz, et al.
1990).
It was Jenson and Jacobson’s preparation of tritiated (3H) estradiol that allowed the
discovery of specific target tissues. They also solidified the receptor concept, which was
crucial in the identification of the first hormone receptor, known as the estrogen receptor
(ER) (Jensen 1962; Toft and Gorski 1966). This group injected (3H)-estradiol into immature
rats and localized the labeled hormone in estrogen responsive tissues including the uterus and
vagina. The radio-labeled hormone was also found in tissue which is now considered to be
unresponsive to estrogen including the liver and kidneys. Moreover, estrogen metabolites
were found in the blood. The non-metabolized form of estrogen was shown to be retained in
target tissues suggesting that it associated with a specific estrogen-binding factor, later
termed the ER, through which estrogen exerts its effects. In contrast, most unresponsive
tissues lack high expression of the ER. Toft and Gorski later confirmed that the estrogen
receptor was in fact a protein (Toft and Gorski 1966). The discovery that a cellular protein
mediates the action of estrogen initiated a series of new studies to characterize the receptor
protein. Collectively, studies on estrogen and its signaling pathways provide valuable
insights concerning hormone action in the vertebrate endocrine system.
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Estrogen receptor structure
The human Estrogen Receptor (hER) was originally cloned and sequenced in 1986
from the MCF-7 breast cancer cell line (Green, et al. 1986). The sequence was found to
contain 595 amino acids with a predicted molecular weight of 66 kDa and its locus was later
mapped to chromosome 6 band q25.1 (Menasce, et al. 1993).
The hER is a member of the steroid/thyroid hormone family of ligand-dependent
transcription factors, which includes the thyroid receptor (TR), the androgen receptor (AR),
the progesterone receptor (PR), the glucocorticoid receptor (GR), and the vitamin D receptor
(VDR) (Evans 1988). The gene coding members of this superfamily have six distinct
functional domains, designated A through F (Figure 1.6) (Beato, et al. 1995).
The N-terminal (A/B) domain of the nuclear receptor family is highly variable in
sequence and length and usually contains a transactivation function, AF-1, which activates
target genes by directly interacting with either components of the core transcriptional
machinery, or coregulators that mediate signaling to downstream effectors. The AF-1 region
of the ER has been implicated in ligand-independent activation.
The highly conserved DNA-binding domain, DBD, or (C) region contains two type II
zinc fingers; the first of which is thought to confer binding specificity, while the second zinc
finger is considered to be responsible for stabilizing binding to DNA through its interaction
with the phosphate backbone on DNA (Umesono and Evans 1989; Zilliacus, et al. 1995). The
C region also plays a role in hER dimerization when the receptor is bound to DNA
(Schwabe, et al. 1993). The nuclear localization sequence for the hER is located downstream
of the C region in the variable hinge region (D). The hinge region allows the hER protein to
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Figure 1.6. Schematic Representation of the Functional Domains of ER. Members of
this receptor family contain six functional domains, termed A-F. The location of the DNA
binding (DBD) and ligand binding (LBD) domains are indicated. The positions of the
activation function domains (AF-1 and AF-2) and the sites involved with dimerization are
also shown. The nuclear localization and the hinge region are found in the D domain. Heat
shock proteins and coactivators interact with the receptor through the E domain.
NH2 CO2HA/B AF1 C D E AF2 F
DNA Binding _________
Ligand Binding ________________________
Dimerization __ __ ______
Hsp Binding _________________
Transactivation _________ ________________________
Silencing _______________
Nuclear Translocation ____ __ ______
TFIIB Binding ___________ _________________
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bend and/or alter its conformation on DNA in the presence of ligand(Kumar, et al. 1987;
Picard, et al. 1990).
As compared to other domains, the ligand-binding domain, LBD, or (E) region is the
largest (~250aa) and least conserved domain of the nuclear receptor family. This domain
contains regions important for ligand binding, homodimerization, nuclear localization,
activating function-2 (AF-2) transactivation, interaction with heat shock proteins such as
HSP90 (in the absence of ligand) and interactions with coregulators (in the presence of
ligand) (Glass, et al. 1997; Pratt 1998; Pratt and Toft 1997). The AF-2 region of the ER is
directly activated in response to the binding of a ligand, and is therefore considered to be
activated in a ligand dependent manner. Finally, at the C-terminal end of the receptor is the
variable (F) region, for which no specific function has been identified, other than
contributing to the transactivating capacity of the receptor (Enmark and Gustafsson 1999).
The deletion of this region does not affect the function of the hER, as determined by reporter
assays (Kumar et al. 1987).
Transcriptional activity of the estrogen receptors is mediated through two distinct
domains termed activation function-1 (AF-1), located in the A/B domain, and activation
function-2 (AF-2), located in the E domain. The AF-1 domain can influence transcription
independently of ligand (Pham, et al. 1992; Tora, et al. 1989). In contrast, the activity of the
AF-2 domain is ligand dependent (Pham et al. 1992; Tora et al. 1989). The function of AF-1
and AF-2 depends on several factors including the type of cell and promoter (Tzukerman, et
al. 1994). The AF-1 region is also the site for ligand-dependent phosphorylation and may
play a role in regulating ER transactivation by affecting the interaction of proteins involved
with regulating ER transcription (Ali, et al. 1993; Le Goff, et al. 1994). Recently, a third
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region with transcriptional activation activity (AF-2a), which functions without activation by
ligand or external stimuli, was found in the N-terminal region of the E domain (Norris, et al.
1997).
Crystal structure of the ligand-binding domain
Important insight into the response of the ER to various compounds has come from
studies of the ligand-binding domain (LBD) utilizing X-ray crystallography. These studies
revealed that the ER LBD is similar to those described for other members of the nuclear
receptor superfamily (Renaud, et al. 1995; Wagner, et al. 1995; Wurtz, et al. 1996). Studies
on the ER revealed that its LBD consists of 12 -helices (H1-H12), and a -sheet forming a
hydrophobic ligand-binding pocket. The -helices of the ER LBD are arranged into a three-
layer structure. The central portion of the structure is composed of helices 5, 6, 9, and 10, and
is sandwiched between helices 1-4 and helices 7, 8, and 11 (Brzozowski, et al. 1997). The
overall structure is conical with the ligand-binding interface located within a narrow portion
of the pocket. Helix 12 is near the binding interface but points away from the conical
structure. Upon estrogen binding, the LBD undergoes major conformational changes,
resulting in the creation of a dimerization surface. This dimer interface consists of amino acid
residues from H7, H8, H9, and H10/11(Tanenbaum, et al. 1998). During this conformational
reorganization, helix 12 closes the binding pocket and creates a site where coactivators can
interact with AF-2. Thus, ligand-induced repositioning of H12 appears to influence the
recruitment of coactivators.
Many anti-estrogens, including Tamoxifen and Raloxifen, are able to bind within the
same pocket of the LBD as 17-estradiol. However, the resulting conformational change of
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the LBD is different from that induced by 17-estradiol, with the major difference being the
positioning of H12. In the presence of antagonists, Tamoxifen and Raloxifene, helix 12 is
displaced from the binding pocket, disrupting the site where coactivators interact with AF-2
(Brzozowski et al. 1997; Shiau, et al. 1998). This raises the possibility that this conformation
of the LBD and particularly the positioning of H12 is determined by the chemical bound to
the LBD.
Estrogen receptor subtypes
A second ER subtype, ER, was described in 1996 and the gene coding for it was
mapped to chromosome 14 band q22-24 (Enmark, et al. 1997; Kuiper, et al. 1996). ER
contains 530 amino acids with a predicted molecular weight of 59.2 kDa. The estrogen
receptor beta (ER) shares significant homology with its counterpart hER, now known as
ER. Despite the homology between the receptors, two different chromosomes encode the
receptors, which rules out the possibility that they are splice variants.
As shown in Figure 1.7, the gene for ER also has six domains comparable to those
of the steroid/thyroid hormone family of ligand-dependent transcription factors, including
ER. There is remarkable conservation of the DNA-binding domain (DBD) between the two
estrogen receptors, which suggests that they should be able to bind similar sequences within
the promoters of estrogen-induced genes. The least conserved domain when comparing the
two ER subtypes is the ligand-binding domain (LBD), which has 55% homology. This
suggests that the receptors may bind ligands with different affinities. ER also lacks an
efficient AF-1 region, which influences the interaction with coactivators that affect ligand
responsiveness of the receptor (Hall and McDonnell 1999).
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Figure 1.7. Schematic representation of the functional domains of ER and ER. As
members of the steroid/thyroid hormone family of receptors, the ERs are divided into six
functional domains termed A-F. ER is composed of 595 amino acids, while its counterpart
ER is composed of 530 amino acids. Each functional domain is indicated in the boxes within
ER (See figure 1.6 for the names of the domains) and the percent homology between the
receptors is indicated in ER. The DNA binding domain maintains significant homology
between the receptors, while the ligand binding domain and N-terminal domain share less
homology.
NHD DBD Hinge LBD F hER
16 97 30 59 18 hER
1 185 251 355 549 595
1 45 148 214 304 500 530
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The physiologic relevance of ER is less well understood than its counterpart ER.
While ER is abundantly expressed in estrogen responsive female tissues such as the ovaries,
uterus, vagina, and mammary glands, ER appears to be highly expressed only in the ovaries.
Insight into the roles of the ERs from mouse models
Tremendous insight into the distinct roles of the estrogen receptor subtypes have
come from the use of mouse models. In the immature uterus of wild-type mice, ER and ER
are equally expressed in both the epithelial (luminal and glandular) and stromal
compartments. However, when these mice are treated with estrogen there is a decrease in
ER expression within the stromal compartment, suggesting that estrogen negatively
regulates this receptor in the mouse (Weihua, et al. 2000). As mice mature, ER mRNA and
protein become highly expressed in the uterine epithelial, stromal, and smooth muscle
compartments. On the other hand, ER mRNA and protein are expressed at much lower
levels than its counterpart within the same uterine compartments, suggesting that ER is the
dominant receptor in the mature tissue (Couse, et al. 1997; Shughrue, et al. 1998). When
stimulated with estrogen, the wild-type rodent uterus reveals an induction in DNA synthesis
and an increase in gene expression of estrogen responsive genes such as the progesterone
receptor (PR), lactoferrin, and glucose-6-phosphatase dehydrogenase (Couse, et al. 1995;
Kastner, et al. 1990; Liu and Teng 1992).
Data obtained from the use of mouse gene knockout technology has provided
considerable insight into the distinct roles of the estrogen receptors in the rodent uterus. Dr.
Oliver Smithies’ and other laboratory groups have generated mice that carry null mutations
in either or both ER subtypes in an effort to identify the roles of each receptor in normal
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rodent physiology. A brief description of the phenotypic expression and general conclusions
into the roles of both receptors elucidated from these studies is presented here.
The first ER knockout mice to be developed were those with null mutations in the
ER gene (ERKO). These mice develop uteri, which contain the epithelial, stromal, and
myometrial compartments (Lubahn, et al. 1993). However, the compartments within the
organ are diminished in size and insensitive to estrogens, as they fail to induce DNA
synthesis and estrogen responsive genes in response to pharmacologic doses of estrogen or a
synthetic agonist, diethylstilbestrol (DES) as seen in wild-type littermates (Lubahn et al.
1993). The ERKO mice are infertile, suggesting an important role for proper ER signaling
within the female reproductive tract. This finding suggests that ER is an important mediator
of both normal cellular proliferation and estrogen-mediated gene regulation within this organ.
ER knockout (ERKO) mice develop normal uteri containing epithelial, stromal,
and myometrial compartments (Krege, et al. 1998). However, unlike the ERKO mice
ERKO mice maintain hormonally responsive uteri. These mice exhibit an increase in Ki-67
protein, a cell proliferation marker, and an exaggerated response to estradiol, suggesting that
ER may play an important role in modulating the effects of ER and may also provide an
antiproliferative function in the immature uterus (Walker and Korach 2004). The ERKO
mice are considered subfertile as they have a reduction in the frequency and size of litters, as
compared to wild-type littermates. Subfertility in these mice is not thought to be linked to the
lack of ER activity in uterine function; rather, it is thought to be mediated by the loss of the
receptor protein expression and activity in the ovary.
More recently, a group of mice was developed with an ER and ER double
knockout (ERKO) genotype. Mice containing the double knockout are viable and possess
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an exaggerated ERKO phenotype (Dupont, et al. 2000). It was noted that the mice have
developed uteri with a reduction in the diameter and myometrial thickness of the organ.
Despite carrying the normal uterine structures, ERKO mice are infertile indicating the
importance of both ER subtypes in normal rodent uterine biology and reproduction.
Taken together, studies using the ERKO mice demonstrate specific phenotypes in the
absence of either or both receptor subtypes within the uteri of mice. In ERKO mice, which
only express ER, investigators noted hypoplastic uteri that were insensitive to estradiol,
suggesting that ER is an important mediator of both cellular proliferation and estrogen
mediated signaling within this tissue. On the other hand, increased cell proliferation and
exaggerated response to estradiol in ERKO mice, which express only ER, suggests that
ER may play an important role in modulating the effects of ER and may also provide an
antiproliferative function within the uterus (Walker and Korach 2004). Additionally, ER can
serve some essential roles of ER in fertility, but ER cannot substitute for ER as ERKO
mice are infertile.
Stromal ER is essential for 17-estradiol induced epithelial proliferation
Over the past decade our understanding of the proliferative response of the epithelium
of the uterus and prostate to mitogenic signaling from steroid hormones has increased
tremendously (Cooke, et al. 1997; Cooke, et al. 1987). Work completed by Cooke et. al.
(1997) provides strong evidence that the “epithelial ER alone is neither necessary nor
sufficient for uterine epithelial mitogenic response to 17-estradiol” (Cooke et al. 1997). To
reach this conclusion, stromal and epithelial cells from ERKO mice (ko) and neonatal ER-
positive wild-type (wt) BABL/c mice were used to construct tissue recombinants. The
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recombinants were constructed to contain ER in the epithelium and/or stroma, or to
completely lack ER expression: wt-stroma + wt-epithelium, wt-stroma + ko-epithelium, ko-
stroma + ko-epithelium, and ko-stroma + wt-epithelium. Tissue recombinants were grown as
grafts in female nude mice and treated with 17-estradiol or vehicle.
The results revealed a similar increase in proliferation of tissue recombinants
containing wt-stroma + wt-epithelium, and wt-stroma + ko-epithelium. This finding indicates
that stromal cells release paracrine factors in response to estrogen, which lead to increased
epithelial growth, even when the epithelium lacks ER expression. Furthermore, tissue
recombinants containing ko-stroma + ko-epithelium, and ko-stroma + wt-epithelium, failed
to induce proliferation in response to 17-estradiol, despite the fact that the wt-epithelial cells
have ER expression.
The tightly regulated paracrine mediated response to steroid hormones in the normal
uterus appears to be absent in disease settings, including hyperplasia and cancer. Rather than
responding to paracrine-mediated factors emanating from stromal cells, epithelial cells begin
to respond directly to 17-estradiol. In fact, the epithelium begins to release paracrine factors
that diminish the stromal compartment, indicating that the normal tissue microenvironment
has been drastically altered. The exact mechanism of this change is not well defined within
this tissue. However, I will provide a plausible mechanism whereby the stromal cells lose
control and the epithelial cell gain the ability to respond to estrogens in Chapter II of this
dissertation.
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Decreased ER expression in cancer
Recent studies have shown alterations in the ER/ER ratio in both estrogen
responsive and nonresponsive cancers. Typically, alterations were demonstrated by showing
a decrease in expression of ER mRNA, protein, or both in tumor versus normal tissues in
several cancers including breast, ovary, colon, and prostate (Bardin, et al. 2004;
Brandenberger, et al. 1998; Campbell-Thompson, et al. 2001; Fixemer, et al. 2003; Foley, et
al. 2000; Horvath, et al. 2001; Latil, et al. 2001; Park, et al. 2003; Pujol, et al. 1998; Roger, et
al. 2001; Rutherford, et al. 2000; Zhao, et al. 2003). A second mechanism for an alteration of
the ratio between the receptors is an increase in ER mRNA, protein, or both. Regardless of
the mechanism, the ER/ER ratio seems to increase in both estrogen sensitive and non-
sensitive tissues during carcinogenesis, suggesting distinct, and possibly divergent, roles for
ER and ER (Leygue, et al. 1998).
Several groups have studied this phenomenon in estrogen responsive tissues, namely
the breast and ovary, and have found an overall disruption in the ratio of ER to ER in
disease states associated with these tissues. A group using immunohistochemistry (IHC) to
study this in the human breast found a higher percentage of ER positive epithelial cells in
normal mammary glands when compared to those found in biopsies from patients with
nonproliferative Benign Breast Disease (BBD), proliferative BBD, or carcinoma in situ
(Roger et al. 2001). This study also noted an increase in ER protein expression in diseased
specimens, and an inverse correlation of ER with Ki-67, a marker of proliferation; together
this may indicate that a loss in expression of ER leads to increased cellular proliferation
(Roger et al. 2001).
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Complementary studies addressing the status of the estrogen receptors in ovarian
tissues have found alterations in the expression of ER mRNA and protein to be associated
with ovarian disease. Normal ovaries express higher levels of ER protein than ER,
indicating that ER is the dominant receptor in this tissue (Kuiper et al. 1996). Data from
many groups suggest that a proper balance between the two receptor subtypes is essential for
the maintenance of normal ovarian function. Comparing biopsies of normal and metastatic
ovarian cancer, one group demonstrated that both ER protein expression, as measured by
Western immunoblot analysis, and mRNA were absent in samples of metastatic ovarian
cancer (Rutherford et al. 2000). This finding suggests that a reduction or loss of the ER
receptor is common in the development of metastatic ovarian disease.
In the human colon, which is generally thought to be an estrogen insensitive organ,
epidemiological studies suggest that estrogens may decrease the risk of developing cancer
(Calle, et al. 1995; Grodstein, et al. 1999). ER is expressed at higher levels in the colon than
its counterpart ER, again suggesting that ER is the dominant subtype in this tissue.
Therefore, the protective effects of estrogen in this tissue may be mediated through the 
receptor subtype. Using IHC and Quantitative Real Time-PCR (qPCR) several studies found
that ER mRNA and protein expression decrease significantly in colon adenocarcinoma
compared to their expression in the neighboring normal colonic epithelium (Campbell-
Thompson et al. 2001). Furthermore, evidence suggesting a progressive decline in ER
expression, which paralleled the loss of malignant colon cell differentiation, has been
suggested by one group (Konstantinopoulos, et al. 2003).
In the development of prostate cancer, which has classically been thought to be an
androgen mediated process, evidence now suggests that estrogens are important mediators in
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the initiation and/or progression of the disease (Jarred, et al. 2000). A recent study found
ER and ER mRNA in all primary cultures of normal human prostate epithelial cells
(Pasquali, et al. 2001). However, when primary malignant epithelial cells were assayed for
expression of the ERs, the group found that only 17% of samples of cancer maintained
expression of ER. Further studies used Western immunoblot analysis to determine the
protein expression of the receptors within the same primary cultures. Ultimately, the findings
suggested that expression of ER, and not ER, is lost in primary cultures of malignant
prostate epithelial cells.
Taken together, studies completed in the ovary, breast, colon, and prostate all suggest
a decrease in ER mRNA and protein expression during carcinogenesis. An exact
mechanism for a reduction or loss of ER has not been proposed or evaluated in great detail.
However, these studies strongly suggest a protective role for ER against the mitogenic
activities of estrogens in estrogen responsive and non-responsive tissues.
Literature on this phenomenon in the human endometrium is scarce and all fail to
include hyperplastic tissue samples, which are precursors for type-1 endometrial cancers
(Fujimoto, et al. 2002; Mylonas, et al. 2005; Utsunomiya, et al. 2000). Moreover, these
studies tend to favor evaluating mRNA levels by in situ hybridization or the reverse
transcriptase-polymerase chain reaction (RT-PCR), as opposed to evaluating the levels of
receptor protein by IHC. Fujimoto et. al. (2002) provided results suggesting that there was no
change in the ratio of the receptors (ER to ER) between normal and malignant samples
(Fujimoto et al. 2002). However, the same group found that the ratio in metatstatic lesions
was significantly higher than in primary cancers. A separate study by Mylonas et. al. (2005)
suggests that the ratio decreases significantly from normal to malignant, which indicates that
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this change involves an increased proportion of ER (Mylonas et al. 2005). The final study
evaluating the expression of the ER receptors was completed by Utsunomiya, et. al. (2000).
This study used IHC, RT-PCR, and in situ hybridization to evaluate the levels of the receptor
subtypes in normal and malignant samples. The results from this study revealed an increase
in the mRNA levels of both receptors in the cytoplasm of carcinoma cells compared to
normal cells (Utsunomiya et al. 2000). Thus, the primary concerns with previous studies are
two-fold: first, they omit a critical step in endometrial cancer progression, and second, the
data from each study seems to be inconsistent. The issue of ER expression in the
progression of type-1 endometrial cancers will be addressed further in Aim 1 of this
dissertation.
Reduction of proliferation by the estrogen receptor 
Although the specific actions of ER in cancer are not known, considerable evidence
obtained from ERKO mice and the reduction/ablation of its protein in human cancer
progression suggests that this receptor may have inhibitory effects on gene regulation and
cellular proliferation. Recent work completed in MCF-7 and T47D, two ER positive breast
cell lines, suggest that introduction of an ER gene construct into cells inhibits breast cell
proliferation and gene transcription (Paruthiyil, et al. 2004; Strom, et al. 2004). One group
produced stable transformants of MCF-7 cells expressing ER or ERcx, an isoform that is
truncated at the C-terminal region. In this study, expression of either ER construct resulted
in a reduced S phase population as compared to the parental cells (Omoto, et al. 2003). In an
effort to elucidate the mechanism for these actions, several groups provide evidence that ER
may reduce proliferation by inhibiting the cyclin D1 gene, a key mediator of the G1-S
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transition of the cell cycle (Strom et al. 2004). In fact, luciferase and transient expression
studies conducted in HeLa cells, a cervical cancer cell line, suggested that treatment with
17-estradiol increased cyclin D1 through ER and decreased its expression through ER
(Liu, et al. 2002). Furthermore, when both receptors were transiently expressed, ER
maintained its ability to negatively regulate the cyclin D1 gene. Another laboratory
evaluating proteins in breast cells by Western immunoblot analysis implicated negative
regulation of several other proteins involved in regulation of the cell cycle, e.g. cyclin E and
Cdc25A, by the ER (Strom et al. 2004). Additionally, it was reported that stable
transformants expressing ER showed a reduction of cathepsin D and IGFBP4, two estrogen
responsive genes, indicating that ER modulates ER activity in breast cancer cell lines.
ER actions
Steroid receptor coactivators
Coactivators are proteins that bind to members of the steroid/thyroid hormone family
of ligand-dependent transcription factors and modulate their functional activities. Over the
past several years, the identification of coactivators has revolutionized our understanding of
nuclear receptor action. Receptors, including the ER, glucocorticoid receptor (GR), and the
progesterone receptor (PR), interact with specific coregulators (Robyr, et al. 2000). In fact, it
was found that ER, PR, and GR could inhibit each other’s transactivation when coexpressed
in mammalian cells, suggesting that these receptors compete for functionally limiting
amounts of transcription factors (Meyer, et al. 1989). In an attempt to identify these factors,
the hER ligand-binding domain (LBD) was fused to glutathione-S-transferase (GST) and
bound to glutathione affinity matrix (Cavailles, et al. 1994; Halachmi, et al. 1994; Hanstein,
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et al. 1996). These studies identified a new class of hER binding proteins from mammalian
cells with molecular weights of 140 KDa (RIP 140), 160 kDa (ERAP 160), and 300 kDa
(p300). These proteins bound to the ER-LBD in the presence of ligand and in an AF-2
(ligand-dependent) manner (Glass et al. 1997). Further studies using the glucocorticoid
receptor (GR) bound to a GR response element identified proteins from nuclear extracts that
associated with the receptor (Eggert, et al. 1995). These proteins were termed GR-interacting
proteins (GRIPS). Subsequently, Thyroid hormone Receptor (TR)-associated proteins
(TRAPS) were identified by immunoprecipitation of an epitope-tagged TR (Fondell, et al.
1996). Some coactivators were also shown to be recruited in a ligand-independent manner by
the AF-1 domain of the ER (Fondell et al. 1996; Tremblay, et al. 1999). The interaction
between the nuclear receptors and coregulators has been linked to the LXXLL interacting
motifs (where L is Leucine and X is any amino acid) of the coregulators with the AF-2
region of the receptor. Coactivators are believed to enhance transactivation of the nuclear
receptors by bridging the receptor with the basal transcription machinery of the cell.
The p160 family of coactivators has been strongly implicated in the transcriptional
activity of the ER. At least three subclasses of coactivators have been identified within the
p160 family and are grouped based on their sequence homology: SRC1 (steroid receptor
coactivator-1)/NcoA-1 (Hong, et al. 1997; Onate, et al. 1995; Torchia, et al. 1997; Voegel, et
al. 1998), TIF2 (transcriptional intermediary factor 2)/GRIP1/NcoA-2 (Hong et al. 1997;
Kim, et al. 1998; Voegel et al. 1998) and AIB1 (advanced in breast cancer
1)/ACTR/pCIP/xSRC-3 (Anzick, et al. 1997; Chen and Evans 1995; Jenster 1998; Kim et al.
1998; Torchia et al. 1997). Coregulators function at the molecular level through enzymatic
activities. Evidence suggests that SRC1 and AIB1 of the p160 family possess histone acetyl
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transferase (HAT) activity in vitro (Jenster 1998; McKenna, et al. 1999). In addition, the
p160 family members bind and recruit other coactivators with HAT activity, i.e. p300. HAT
activity acetylates histones which assist in euchromatization, or “relaxation,” of the
chromatin structure. This change permits the basal transcription machinery to have access to
the site, eventually leading to transcription or increased transcription.
Estrogen-response elements
After being activated by its ligand, the activated ER binds to estrogen-response
elements found within the promoter of target genes. This binding induces transcription or
repression of the gene. The classic ERE sequence was first discovered in the Xenopus laevis
vitellogenin A2 promoter and was found to be composed of two palindromic half-sites
separated by three nucleotides, 5’AGGTCAnnnTGACCT3’, where n can be any nucleotide
(Klein-Hitpass, et al. 1986). To date, the only human estrogen responsive genes that contain
“perfect” response elements are EBAG9, COX7A2L, and EFPa/ZNF-147 (Bourdeau, et al.
2004; Ikeda, et al. 2000; Inoue, et al. 1993; Klinge 2001; Watanabe, et al. 1998).
More recently, a new subclass of response elements have been identified which
appear to have diverged from known Alu sequences. The Alu family of short interspersed
DNA elements are the most abundant mobile elements distributed throughout the human
genome. McDonnell et. al. (2000) found that Alu elements have the potential to acquire the
ability to function as estrogen receptor-dependent enhancers (Norris, et al. 1995). Generally
speaking, the Alu responsive elements that confer estrogen responsiveness to a specific
region generally contain one perfect ERE half-site.
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Current model of the ER pathway
When not bound by its ligand, the estrogen receptor is located in the nucleus and is
part of a multiprotein complex with several chaperone proteins, including heat shock proteins
HSP90 and HSP70, p23, and immunophilins which serve to stabilize and/or mask the DNA
binding domain of the receptor (Graumann and Jungbauer 2000; Pratt 1998; Pratt and Toft
1997; Smith and Toft 1993). When estrogen enters a responsive cell, it binds to the ligand-
binding domain of the receptor, which undergoes a conformational change that results in the
dissociation of the chaperone proteins (Pratt and Toft 1997). The release of the chaperones
exposes the dimerization and AF-2 transactivation domains present in the E domain
(Beekman, et al. 1993). As a result of a yet unknown mechanism, the estrogen/ER complexes
form functionally active dimers that become-phosphorylated at specific amino acid residues
within the AF-1 domain (Smith 1998). The activated ER dimers then bind specific
sequences, estrogen response elements (EREs), within the promoters of target genes and
initiate transcription or repression of those genes. Homodimerization between two ER’s or
two ER’s is well-recognized and accepted. However, there is no data supporting
endogenous heterodimer formation. Heterodimerization of the two receptors has been
observed in artificial systems in which each receptor was overexpressed and has only been
hypothesized to occur in vivo (Chen and Evans 1995; Cowley, et al. 1997; Hall and
McDonnell 1999; Pettersson, et al. 2000; Pettersson, et al. 1997).
Estrogens also regulate the transcription of genes that lack functional estrogen
response elements (EREs) by modulating the activity of other transcription factors. The
effects of estrogens in this instance are due to tethering of the active ER’s to transcription
factors, such as AP-1 or SP-1 within the promoter region of target genes (Webb, et al. 1995).
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Figure 1.8. Estrogen Receptor Pathway. (1) The inactive ER resides in the nucleus as
part of a protein complex that includes heat shock protein 90 (hsp 90). (2) Upon binding
estrogen, the receptor dissociates from the protein complex. (3) The receptor dimerizes
and becomes phosphorylated. (4) The dimer binds to specific DNA sequences termed
estrogen response elements (ERE) and recruits coactivators to the promoter region of the
gene. The ER regulates gene transcription by interacting with basal transcription factors
and coactivators such as SRC-1 and p300.
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Estrogen receptors have also been shown to interact with the nuclear factor kB (NFkB)
(McKay and Cidlowski 1998; Shyamala and Guiot 1992).
Alternative pathways of the estrogen receptor
Ligand-independent activation of estrogen receptors
The ERs are phosphoproteins whose function can be altered by changes in
phosphorylation in the absence of its endogenous ligand (Campbell, et al. 2001; Kato, et al.
1995; Kato, et al. 2000). Growth factors, i.e. epidermal growth factor (EGF) and insulin-like
growth factor (IGF), have the ability to activate protein kinases, such as MAPK or (PI)3-
kinase, which can induce estrogen-independent activities of the ER by phosphorylating
specific serine residues in the AF-1 region of the receptor.
Evidence supporting ligand-independent activation of the ER stems from an
experiment showing that EGF induction of DNA and lipid synthesis in the uterus could be
prevented by the anti-estrogen ICI 164384 (Kato et al. 2000). The elucidation of the
mechanisms behind the crosstalk between these two independent receptors came from the
observation that molecular events, i.e. activation of MAP-Kinase by EGFR complexes, could
lead to phosphorylation and activation of the ER at Ser118, which is located in the AF1
domain of the protein (Bunone, et al. 1996; Kato et al. 1995; Kato et al. 2000).
Phosphorylation at Ser118 results in activation of genes that are regulated by ER and not
EGFR. Further data implicates activation of (PI)3- kinase by the EGFR complexes, which in
turn phosphorylates ER on Ser167 in the AF1 domain leading to activation of the
ER(Campbell et al. 2001; Martin, et al. 2000).
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Crosstalk between the ER pathway and growth factor pathways
The ligand-dependent estrogen-signaling pathway takes minutes or hours to increase
protein synthesis by transcriptional activation. Recent data in the literature suggests that
estradiol has other effects that cannot be explained by the ligand-dependent mechanism due
to their rapid onsets. Many of these effects, deemed non-classic, have been linked to cell-
surface forms of ER, which are thought to resemble nuclear ER (Kato et al. 1995; Song, et al.
2002; Watson, et al. 1999). There is a body of evidence that links estrogen cell surface
receptors and activation of the mitogen activated protein kinase (MAPK) signaling cascade
(Song et al. 2002; Song, et al. 2005). There have also been reports that link estrogen cell
surface receptors with the rapid activation of the phosphatidylinositol (PI)3-kinase pathway
(Stoica et al. 2003). The non-classic action of the ER provide a direct connection between
estrogen and stimulation of anti-apoptotic/pro-cell proliferation pathways that have been
strongly implicated in carcinogenesis.
Differential activation of the estrogen receptors
The development of several non-steroidal compounds, which have been found to be
highly selective for one ER subtype over the other, have the potential to provide important
insight regarding the differences between the functions of the two estrogen receptors in vivo
and in vitro (Meyers, et al. 2001; Stauffer, et al. 2000). Non-steroidal compounds were
synthesized and characterized as selective agonists or antagonists for ER or ER based on
their binding affinity and ability to transactivate gene constructs containing consensus EREs.
The first compound, diarylpropionitrile (DPN), is an agonist that has a selective effect
on the ER (Meyers et al. 2001). It has been shown that DPN has a 100-fold preference for
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Figure 1.9. Molecular Structures of ER Agonists and Antagonists. Ligands of the
ER used within this dissertation are 1) 17-estradiol (estrogen), an agonist of both ER
subtypes, 2) Propylpryazole-triol (PPT), an agonist of the ER, and 3)
Diarylpropionitrile (DPN), an agonist of ER. Anti-estrogens used within the studies
herein are 1) Methyl-piperidino-pyazole (MPP), a specific inhibitor of ER, and 2) ICI
182780, a potent inhibitor of both ERs.
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ER over ER (Harrington, et al. 2003). The second compound, propylpryazole-triol (PPT),
is an agonist that was found to have a 400-fold preference for ER over ER (Kraichely, et
al. 2000). The ER selectivity of PPT depends on its interaction with several regions of the
ligand-binding domain (Harrington et al. 2003). Lastly, methyl-piperidino-pyazole (MPP) is
a highly selective ER antagonist. The basic side chain responsible for the activities of this
compound is the same side chain found in Raloxifene, an ER antagonist. MPP has a 200-fold
higher affinity for ER over ER and is thus considered a highly selective, potent ER
antagonist.
Hypothesis and specific aims of this dissertation
Unopposed estrogens are considered to be the primary etiologic risk factor for
developing type-1 endometrial cancer. The mechanisms of action of estrogen receptors in the
human uterus are complex and not completely understood. However, evidence generated
using mouse gene knockout models has provided tremendous insight into the divergent roles
of the receptors in the uteri of rodents. Nevertheless, the function of the receptors in the
mouse uterus may not completely correspond with their roles in the human. Therefore, it is
imperative that the roles of each receptor be elucidated in human endometrial cells in an
effort to understand the contributions of each receptor to estrogen-induced disease,
particularly cancer.
Recent evidence suggests that the “normal” ER/ER ratio is altered during human
breast, ovarian, colon, and prostate cancer development. Because of similarities of
endometrial cancer to these other neoplasms it is reasonable to suspect that a similar
mechanism may apply. If this change also occurs in the endometrium it may lead us to a
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mechanism whereby cells bypass the normal homeostatic constraints to induce proliferation,
prevent apoptosis or both. Further observations accumulated using in vitro assays support the
idea that a reduction of ER can lead to increased mitogenic signaling in response to 17-
estradiol. In these studies, introduction of ER attenuates 17-estradiol’s mitogenic signaling
through ER by direct or indirect mechanisms. Attenuation via the direct mechanism
involves heterodimerization of the ERs. This dimer formation leads to a reduction in
estrogen-dependent transactivation of estrogen-responsive luciferase constructs when
compared to ER homodimers (Cowley et al. 1997; Matthews and Gustafsson 2003). The
indirect method involves recruitment of ER homodimers to the promoters of estrogen-
responsive genes, which prevents mitogenic ER homodimers, or ER/ER dimers from
inducing estrogen-dependent transcription. On the basis of these findings, I hypothesize that
ER is a modulator of the activity of ER in the human endometrium. If this is true, we
should note a decrease in activity of estrogen-inducible genes, like placental alkaline
phosphatase (ALPP), and proliferation when ER is introduced into endometrial epithelial
cells.
Hypothesis 1. The ER/ER ratio is altered as the human endometrium transitions from a
normal to a neoplastic condition.
To test this hypothesis, I have:
i. Created Tissue Microarrays (TMA’s) containing normal, hyperplastic, or
neoplastic human endometrial biopsy samples.
ii. Stained separate TMA’s with antibodies against the estrogen receptors  and
.
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iii. Observed and quantified the expression of both estrogen receptor subtypes.
Hypothesis 2. ER activation increases ALPP gene expression in human endometrial
epithelial cells, while ER activation decreases ALPP expression.
To test this hypothesis, I have:
i. Used highly specific agonists of the ER’s in the Ishikawa model system to
elucidate the roles of each receptor in ALPP expression.
ii. Used the isogenic Ishikawa cell lines expressing ER, ER, or both ER’s to
understand the role of both receptors on ALPP gene expression.
iii. Located EREs within the ALPP promoter and used Chromatin
Immunoprecipitation (ChIP) Assays to determine if the receptor subtype(s)
bind this region.
Hypothesis 3. ER activity increases proliferation of human endometrial epithelial cells
while ER activity acts as an inhibitor of proliferation.
To test this hypothesis, I have:
i. Used highly specific agonists of the ER’s in the Ishikawa model system to
elucidate the roles of each receptor in cell proliferation.
ii. Used an isogenic Ishikawa cell line, IK-3H12, which lacks expression of
either ER subtype, I will create stable cell lines expressing one or both ER’s.
iii. Used these stably transformed cell lines to distinguish the roles of each
receptor in the proliferative responses of the endometrium.
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iv. Evaluated the cell cycle progression of the IK-3H12 expressing either ER or
 in response to 17-estradiol.
v. Evaluated estrogen-induced apoptosis by expressing ER, ER or both in the
IK-3H12 cells.
Chapter II. Determine the Relative Levels and Expression Patterns of ER and ER in
Normal, Hyperplastic, and Malignant Endometria
Abstract
Although estrogen is the leading etiologic factor in endometrial cancer, the
mechanistic role of estrogen and its receptors (ERs) in endometrial carcinogenesis are not
thoroughly understood. In the normal human endometrium, ER and ER are expressed in
the epithelial, stromal, and myometrial compartments. However, ER expression tends to be
lower than that of ER in the epithelial compartment. Since the loss of functional ER
expression in the uterus is correlated with an exaggerated response to estrogen in estrogen-
receptor beta knockout (ERKO) mice, the work presented here investigated patterns of ER
and ER expression in normal, hyperplastic, and malignant human endometrial tissue
samples. High density tissue microarrays were constructed using 29 cycling endometria (15
proliferative and 14 secretory), 29 hyperplastic endometria (15 complex and 14 complex with
atypia), and 29 type-1 endometrioid cancer biopsies. ER expression was assayed by
immunohistochemistry (IHC) using high-density tissue microarrays (TMAs) and Dako
antibodies against the ERs. Epithelial and stromal cell nuclear and cytoplasmic ER and ER
immunostaining were assessed semiquantitatively on a scale ranging from 0 (no
immunostaining) to 3 (strong immunostaining) in 100 nuclei or cells, yielding a score
ranging from 0 to 300 for each core. The results contained herein reveal alterations of the
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normal ER/ER ratio in both the stromal and epithelial compartments of hyperplastic and
neoplastic tissues. Specifically, alterations found in hyperplastic samples lead to an increase
in ER expression over that of ER. An alteration within the stroma of hyperplastic
endometrial samples was observed as ER expression remained constant (p=.6660),
compared to normal, while ER expression decreased (p=.0001). Unlike the stromal
compartment, the epithelium revealed an increase in ER expression (p=.0001), compared to
control, while ER expression remained constant (p=.5029), again indicating a mechanism
whereby ER expression is dramatically increased over ER. Furthermore, epithelial cells
from malignant samples revealed a significant increase (p=.0005 and p=.0001) in the
immunostaining of ER and ER, respectively. Collectively, the findings described herein
indicate alterations in the normal ER/ER ratio in the hormonally responsive compartments
of the endometrium. The observed alterations, specifically those in the hyperplastic samples,
may provide a key mechanism which promotes estrogen-mediated carcinogenesis.
Introduction
Endometrial cancer is the most common gynecologic malignancy in the United
States. According to the American Cancer Society approximately 41,200 women will be
diagnosed and 7,350 women will die as a result of this disease in 2007. Approximately ninety
percent of endometrial tumors arise from the luminal and glandular epithelium, while the
remaining ten percent arise from stromal cells. Unopposed estrogen exposure is the primary
etiologic risk factor for the development of endometrial hyperplasia, a precursor for Type-1
endometrial cancer (Montgomery et al. 2004; Rose 1996). The physiologic effects of
estrogens are mediated through two distinct nuclear receptors called the estrogen receptor
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(ER)  and . The response to estrogens, in the normal endometrium, is a tightly regulated
process involving the tissue microenvironment, specifically stromal and epithelial cells.
However, in estrogen-dependent hyperplasia and cancers, there is a disruption of the normal
regulatory interactions of the microenvironment thereby permitting epithelial cells to respond
directly to steroid hormones (Bissell, et al. 1999). To understand the mechanisms of
estrogen-dependent endometrial disease, it is imperative to uncover the individual
contributions of the ERs within the microenvironment.
Over the past decade, our understanding of the proliferative response of the uterine
epithelium to mitogenic signaling from steroid hormones has dramatically increased (Cooke
et al. 1997). In vitro assays studying interactions between stromal and epithelial cells from
the endometrium, breast, prostate, and testis revealed that paracrine factors released from
normal stromal cells regulate the growth of normal epithelial cells when grown in coculture
or when media taken from stromal cells grown in monoculture is introduced into cultures of
epithelial cells growing in monoculture (Arnold, et al. 2001; Fong, et al. 1992; McGrath
1983; Skinner and Fritz 1985). Moreover, stromal cells release specific paracrine factors, in
response to steroid hormones, which directly induce or repress epithelial cell proliferation
(Cooke et al. 1997).
Cooke, et. al. (1997) provide strong evidence that the “epithelial ER alone is neither
necessary nor sufficient for uterine epithelial mitogenic response to 17-estradiol” (Cooke et
al. 1997). To reach this conclusion, stromal and epithelial cells from ERKO mice (ko) and
neonatal ER-positive wild-type (wt) BABL/c mice were used to construct tissue
recombinants. The recombinants contained ER in the epithelium and/or stroma, or to
completely lack ER expression: wt-stroma + wt-epithelium, wt-stroma + ko-epithelium, ko-
49
stroma + ko-epithelium, and ko-stroma + wt-epithelium. Subsequently, tissue recombinants
were grown as grafts in female nude mice and treated with vehicle or 17-estradiol.
The results revealed a similar increase in proliferation of tissue recombinants
containing wt-stroma + wt-epithelium, and wt-stroma + ko-epithelium. This finding indicates
that stromal cells release paracrine factors in response to estrogen, which lead to increased
epithelial growth, even when the epithelium lacks ER expression. Furthermore, tissue
recombinants containing ko-stroma + ko-epithelium, and ko-stroma + wt-epithelium, failed
to induce proliferation of the epithelium in response to 17-estradiol, despite ER expression
in the wt-epithelial cells.
Studies using tissue recombinants have proved useful in our understanding of the
normal response to steroid hormones. However, these studies do not address the individual
contributions of ER or ER in the stroma or epithelium of endometrium. Insight into the
independent roles of the ERs came from studies using Estrogen Receptor Knockout (ERKO)
mice (Dupont et al. 2000; Krege et al. 1998; Lubahn et al. 1993). Initial observations from
these studies indicate specific phenotypes in the absence of either or both receptor subtypes
within the uteri of mice. In ERKO mice, which only express ER, investigators noted
infertile mice with hypoplastic uteri that were insensitive to pharmacologic doses of 17-
estradiol, suggesting that ER is an important mediator of both cellular proliferation and
estrogen mediated signaling within this tissue. On the other hand, increased cellular
proliferation and an exaggerated response to 17-estradiol in ERKO mice, which express
only ER, suggests that ER may play an important role in modulating the effects of ER
and may also provide an anti-proliferative function within the rodent uterus (Walker and
Korach 2004). The information, in combination with the studies conducted by Cooke, et al
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(1997) suggests that ER in the stroma responds to estrogen and in turn releases paracine
factors that induce proliferation of the epithelial compartment.
Following the phenotypic description of ERKO mice, many postulated that ER may
be a modulator of the mitogenic effects of ER within human tissues. If this was true, it was
reasonable to hypothesize that the normal ratio between the two receptors would be altered
during estrogen-dependent disease progression. With that hypothesis, several groups
evaluated the expression levels of the ERs, by immunohistochemistry (IHC) and/or real time
PCR (qPCR), to compare the ratio of the ERs in normal, hyperplastic, and neoplastic tissues.
The described studies have been carried out in breast, ovary, prostate, and colon samples and
have revealed an alteration in the “normal” ER/ER ratio when normal tissues were
compared against hyperplastic and malignant samples (Bardin et al. 2004; Brandenberger et
al. 1998; Campbell-Thompson et al. 2001; Fixemer et al. 2003; Foley et al. 2000; Horvath et
al. 2001; Latil et al. 2001; Park et al. 2003; Pujol et al. 1998; Roger et al. 2001; Rutherford et
al. 2000; Zhao et al. 2003). These findings suggest that the maintenance of a “normal”
ER/ER ratio is critical to the normal homeostatic constraints in response to estrogens.
In summary, information derived from endometrial tissue recombinant studies,
ERKO models and the ER ratio studies suggests several important points. First, there is an
alteration of the normal homeostatic constraints in the endometrial microenvironment as the
tissue transitions toward malignancy. Second, in the uteri of mice, ER may be a key
modulator of the mitogenic effects of ER. And third, an alteration of the ratio between the
ERs may provide a mechanism whereby the epithelium obtains the ability to respond directly
to steroid hormones. What is not known is whether there is an alteration of the ER/ER
ratio as the human endometrium progresses toward malignancy. Because of similarities of
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endometrial cancer to the aforementioned cancers, it is reasonable to suspect that a similar
mechanism may apply. Therefore, the goal of this study is to determine whether an alteration
of the normal ER/ER ratio takes place in endometrial microenvironment as it transitions
from normal toward malignancy. The aim will be accomplished using immunohistochemistry
and semiquantitative analysis to detect expression of the estrogen receptors.
A better understanding of how the epithelial compartment of the endometrium
becomes hypersensitive to estrogens will yield important novel insights into endometrial
carcinogenesis and may lead to the development of novel therapies for endometrial cancer or
strategies to prevent malignant transformation of endometrial epithelial cells.
Materials and Methods
Patient and tissue samples. All endometrial specimens were acquired in compliance
with the guidelines of the University of North Carolina at Chapel Hill Institutional Review
Board (Application#: 05-PATH-866) and the Federal Health Insurance Portability and
Accountability Act (HIPAA) protected health information regulations. Retrospective
paraffin-embedded tissue samples were collected from the University of North Carolina
Department of Pathology and Laboratory Medicine/Lineberger Comprehensive Cancer
Center Tissue Procurement Core Facility following a key word search completed by Mr.
Benjamin Aycock in the Office of Information Systems (OIS) within the School of Medicine.
Specimens collected for the purpose of this study were stripped of patient identifiers and
samples were assigned an anonymous research study number for record keeping. All research
data were entered into a computer protected by password and present within a locked office.
Additionally, all tissue samples were stored under appropriate conditions in locked
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laboratories. A total of 87 endometrial specimens were used to create three independent
tissue microarrays containing cycling, hyperplastic or malignant cores.
Tissue microarray construction. Tissue microarray (TMA) technology was utilized
for the proposed studies within this aim. This technology allows production of a single
paraffin block containing multiple patient samples (Figure 2.1). A recent publication reported
that the use of TMA technology for validating protein expression in the human endometrium
maintained concordance between the TMA and whole slides (Fons, et al. 2006).
In this study, three independent high-density tissue microarrays (TMAs) were
constructed using formalin-fixed, paraffin-embedded human endometrial specimens. Each
TMA contained either normal cycling endometrium (proliferative and secretory),
hyperplastic endometrium (complex and complex with atypia), or endometrial
adenocarcinoma (endometrioid) samples.
To prepare tissue microarrays, paraffin blocks from patients identified only by study
numbers assigned by the principal investigator were obtained for analysis. Six-micrometer
sections were cut from “donor” paraffin blocks and stained with hematoxylin and eosin
(H&E) using routine methods. Dr. Ruth Lininger, a surgical pathologist specialized in
gynecologic pathology, evaluated each coded patient section and identified three
representative areas of interest in each of the normal, hyperplastic, and adenocarcinoma
biopsies. Representative areas of interest were encircled on each slide and 0.6mm tissue
cores were excised from the corresponding sites in the paraffin donor block. The excised
cores were subsequently implanted into a “recipient” paraffin block, with 1mm between each
core, using a manually operated tissue microarray device (Beecher Instruments). Each TMA
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Figure 2.1. Schematic Representation of TMA Process. Recipient blocks containing
multiple patient cores were sectioned, placed onto glass slides, and stained with
individual antibodies against the ERs. After immunostaining, patient cores were excised
digitally and stored as individual high resolution files. Examples of the digital files are
located to the right of the figure.
Recipient Block
Stained Slide
Individual Core
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was constructed with triplicate cores from each patient sample to produce an array containing
approximately eighty-seven cores (Figure 2.1). The recipient block containing the arrayed
cores was then cut into 4µm sections, transferred to glass slides and subsequently stained for
ER and ER.
Immunochemistry. Preliminary studies to optimize primary antibody concentrations
were carried out on normal and neoplastic breast sections. The unstained breast sections were
deparaffinized with xylene and rehydrated through a series of graded alcohols. Antigen
retrieval was carried out in Citra Plus Buffer (BioGenex) for 2 minutes at 120oC.
Endogenous peroxidases were blocked using 3% peoxidase in methanol for 10 minutes. Non-
specific signal was blocked with normal horse serum (Vectastain Elite Kit – M) for 15
minutes at room temperature. Samples were incubated for 30 minutes at 37oC with antibodies
against the ER (Dako, 1D5) at 1:35, or 1:20; or antibodies against ER at 1:20 or 1:10
(Dako, PPG5/10). Sections stained for ER were incubated with Vectastatin LK (Vectastain
Elite Kit - M) for 30 minutes, while sections reacted with anti-ER antibodies were incubated
with Dako LSAB + System HRP. Following exposure to biotinylated secondary antibody,
sections were visualized using streptavidin HRP (Dako LSAB+ System HRP). Reaction with
DAB chromogen was carried out for 2 minutes and slides were counterstained with
hematoxylin. Sections stained with antibodies against ER at 1:20 and ER at 1:10 provided
the optimal staining patterns, and will be used for further studies with TMA’s.
Unstained TMA sections were processed as described above. Sections were incubated
for 30 minutes at 37oC with antibodies against the ER (Dako, 1D5) at 1:20 or ER at 1:10
(Dako, PPG5/10). Normal and neoplastic breast sections were processed alongside the TMAs
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and were used as positive controls for each antibody. Additionally, normal and neoplastic
breast sections not receiving primary antibodies were used as controls for non-specific signal.
An additional section of each tissue array was stained with H&E, using standard procedures
(Figure 2.1).
Image acquisition and analysis. Digital images of TMA’s were captured using an
Aperio Scanscope model T2 (Vista, CA) which allows one to scan an entire slide at high
magnification and store the information digitally. TMA digital images were subsequently
saved as .tiff image files and Aperio software (Vista, CA) was used to open and analyze each
digital image. This software allows the user to evaluate the digital images at various
magnifications. Subsequently, individual cores from each TMA were digitally separated
using Aperio’s TMA Lab software (Figure 2.1). After separation, each core was given a
random identification number, which was known only by the principle investigator.
Randomized digital TMA cores were provided to an experienced observer (O. Harris
Ford) as .tiff images. The files were analyzed by the observer so they were blinded to the
type of antibody and to the identity of the tissue sections. Moreover, O. Harris Ford was
blinded to the details and expected outcomes of the study. Additionally, Dr. Ruth A. Lininger
reviewed random images to ensure that scoring was uniform. Epithelial and stromal cell
nuclear and cytoplasmic ER and ER immunostaining was semiquantitatively assessed on a
scale ranging from 0 (no immunostaining) to 3 (strong immunostaining) in each of 100 nuclei
or cells, yielding a score ranging from 0 to 300 for each feature for each specimen (Figure
2.2) (Majumder, et al. 2006).
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Figure 2.2. Examples of Nuclear Immunohistochemical Staining Intensities.
Excised from core 36, indicating nuclei with immunoscores of 0, 1, 2 and 3. Nuclear
intensity scoring was as follows: 0=hematoxylin only; 1=Light staining; 2=Moderate
staining; 3=Intense staining.
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Statistical analysis. Data were obtained as the mean visual scores of ER and ER
immunostaining. Student’s t test was used to compare ER or ER nuclear and cytoplasmic
immunostaining between normal and hyperplastic, normal and neoplastic, or hyperplastic and
neoplastic samples. Following the initial Student’s t test, ANOVA analysis (Tukey HSD
Multiple Comparison test) was carried out to compare the staining between all three groups.
Differences were considered to be significant at P < 0.05.
Results
Internal Review Board (IRB) approval. An application was submitted to the
University of North Carolina at Chapel Hill Institutional Review Board (IRB) for permission
to obtain retrospective endometrial tissue biopsies to pursue the study of the expression
levels of the estrogen receptors in the human endometrium. Following review of this
application, the UNC-IRB granted approval (#: 05-PATH-866) to pursue the proposed
studies for one calendar year.
Immumohistochemical Staining of the TMA’s
Cyclic endometrial samples. Immunohistochemical staining of cyclic endometrial
samples with antibodies against the ER subtypes revealed staining in both the epithelial and
stromal compartments. Maximum staining of ER was seen in cores from the proliferative
phase of the menstrual cycle and a reduction in immunostaining became apparent during the
secretory phase of the menstrual cycle. Immunostaining for ER followed the same overall
trend as its counterpart in the cycling endometria. However, ER expression remained
considerably lower than that of ER in the epithelial compartment. The observations in the
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cycling endometria described are consistent with the findings of others (Lessey et al. 1988;
Mylonas, et al. 2004).
Stromal immunohistochemical staining. Nuclear ER immunostaining in the stromal
compartment revealed no significant change in immunostaining intensity between normal
and hyperplastic cores (p=.6660). However, a significant decrease in staining intensity was
observed (p=.0009) in the nuclei of stromal cells from malignant cores. Median intensity
scores of 114 in normal (n=27), 129 in hyperplastic (n=20), and 46 in malignant (n=21) cores
were obtained following data analysis (Figure 2.3a). On the other hand, nuclear ER
immunostaining in the stromal compartment decreased in the hyperplastic cores (p=.0023)
compared to normal, while malignant samples revealed a significant increase in
immunostaining intensity as compared to normal (p=.0093). Median intensity scores of 162
in normal (n=22), 48 in hyperplastic (n=17), and 267 in malignant (n=22) cores were
observed (Figure 2.3b). The range of scores for nuclear ER and ER in the stromal cells of
normal, hyperplastic, and neoplastic are shown in Figure 2.4 a-f.
Cytoplasmic ER immunostaining in the stromal compartment revealed that
approximately 5% of normal cells were positive, while there was no immunostaining
detected in hyperplastic or malignant samples. On the other hand, 0% of normal stromal cells
stained for cytoplasmic ER. However, an increase in ER cytoplasmic immunostaining, of
5.6% and 10%, in the hyperplastic and malignant samples was observed, respectively
(Figures 2.3 c and d).
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Figure 2.3. Results of ER and ER Immunostaining in Endometrial Stromal
Cells. Box and Whisker plots reveal the top and bottom quartiles, in addition to the
minimum, maximum, and median scores for ER staining in the nuclei of stromal cells
(A and B). Cytoplasmic staining of the stromal cells was recorded and graphed as
percent positive cells (C and D).
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Figure 2.4. Distribution of Stromal Nuclear Immunostaining Scores. (A-C,
Stained with antibodies for ER) A) Normal B) Hyperplastic C) Neoplastic (D-
F, Stained with antibodies for ER) D) Normal E) Hyperplastic F) Neoplastic.
Immunointensity is located on the Y-axis and patient numbers are located on the
X-axis.
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Epithelial immunohistochemical staining. Nuclear ER immunostaining in the nuclei
of epithelial cells revealed a significant increase in intensity in hyperplastic and malignant
tissues (p=.0001 and p=.0005, respectively) as compared against normal tissues. Median
intensity scores of 155, 281, and 243 where observed in normal (n=27), hyperplastic (n=20),
and malignant (n=21) cores, respectively (Figure 2.5a). Unlike ER nuclear staining in the
epithelial compartment, ER remained constant in the hyperplastic samples before increasing
dramatically in malignant cores (p=.0001). Median intensity scores for ER nuclear epithelial
staining were 73, 119, and 300 in normal (n=22), hyperplastic (n=17), and malignant (n=22)
cores, respectively (Figure 2.5b). The range of scores of nuclear ER and ER nuclear
staining scores are shown in Figure 2.6 a-f.
Epithelial cytoplasmic immunostaining for ER resulted in 13% of normal cells and
61% of hyperplastic samples staining as positive. Interestingly, there was a reduction to 22%
positive cells in the malignant samples. On the other hand, 55% of normal epithelial cells
presented cytoplasmic ER staining, while hyperplastic samples revealed a slight reduction
to 43%. Moreover, a significant increase in cytoplasmic ER staining in the malignant
epithelial cells was observed, where 91% of epithelial cells were positive (Figures 2.5 c and
d).
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Figure 2.5. Results of ER and ER Immunostaining in the Endometrial Epithelial
Compartment. Box and whisker plots reveal the top and bottom quartiles, in addition to
the minimum, maximum, and median scores for ER staining in the nuclei of epithelial cells
(A and B). Cytoplasmic staining of the epithelial cells was recorded and graphed as percent
positive cells (C and D).
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Figure 2.6. Distribution of Epithelial Nuclear Immunostaining Scores. (A-C,
Stained against ER) A) Normal B) Hyperplastic C) Neoplastic (D-F, Stained against
ER) D) Normal E) Hyperplastic F) Neoplastic. Immunointensity is located on the Y-
axis and the number of patients is located on the X-axis.
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Discussion
Estrogens have been implicated in the initiation and/or progression of type-1
endometrial cancers for at least two decades (Rose 1996). The physiologic effects of
estrogens are mediated by two distinct transcription factors known as the estrogen receptors
(ERs)  and  (Enmark et al. 1997; Green et al. 1986; Kuiper et al. 1996). To date, the
functions of the ERs in the normal and abnormal endometrium remain largely unresolved.
However, evidence gathered using estrogen receptor knockout mice (ERKO) reveal that the
ER subtypes may maintain divergent roles (Dupont et al. 2000; Krege et al. 1998; Kuiper et
al. 1996). ERKO mice display hypoplastic uteri that fail to respond to pharmacologic doses
of estrogens, suggesting that ER may be the key mediator of proliferation within this tissue.
On the other hand, ERKO mice have hyperplastic uteri that produce an increased response
to estrogens, suggesting that ER may modulate ER’s stimulatory properties. Taken
together, data from both in vivo and in vitro studies suggests that ER and  have divergent
roles with regard to gene regulation and proliferation.
In the current study, we assessed ER and ER immunostaining in the nuclear and
cytoplasmic compartments of normal, hyperplastic, and malignant endometrial stromal and
epithelial cells. Unlike the epithelial compartment, the stromal compartment from normal
endometrial cores revealed stronger immunostaining for ER than ER. However, stromal
cells from hyperplastic samples revealed a marked decrease in ER intensity and while ER
immunostaining remained constant, indicating that an alteration of the “normal” ER/ ER
ratio occurs within this compartment (Table 2.4). We believe this alteration of the ER/ER
ratio to be a key step in the initiation and/or progression of estrogen-dependent endometrial
cancer. Work published by Arnold et al. has shown that paracrine factors from normal
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Table 2.2. Average Nuclear ER Immunoscores for Stromal Cells. Normal (n=27),
Hyperplastic (n=20), and Neoplastic (n=21).
23151
77122
158112
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Table 2.3. Average Nuclear ER Immunoscores for Epithelial Cells. Normal
(n=27), Hyperplastic (n=20), and Neoplastic (n=21).
222222
121251
100143
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stromal cells regulate the proliferation of both normal and diseased endometrial epithelial
cells in vitro in response to treatment with 17-estradiol (Arnold et al. 2001; Arnold, et al.
2002). Therefore, alterations in the microenvironment of hyperplastic endometrial tissue
must occur to allow the epithelial compartment to continue its abnormal growth in response
to estrogens. Additionally, alterations in the expression profiles of the stromal receptors in
malignant samples are probably not as significant because the stromal compartment becomes
reduced in size at this stage of estrogen-dependent endometrial disease.
The epithelial compartment of normal endometrial tissues revealed stronger
immunostaining for ER than ER. However, within the hyperplastic tissue there was a
dramatic increase in the immunoreactivity of ER while ER immunostaining remained
relatively constant, indicating that an alteration of the normal ratio had taken place (Table
2.3). Again, this alteration takes place at a critical junction for estrogen-dependent
endometrial disease. The current literature suggests that ER is a key stimulator of growth
while ER is an inhibitor of growth in the human breast and ovary, and from these findings
we believe this to be true also in the human endometrium. Finally, we believe that the final
increase of ER in malignant tissues may be a protective response by the cell to curb
uncontrolled growth in response to 17-estradiol. However, cells at this stage of the disease
may have acquired key cellular alterations to overcome ER’s protective function and exploit
any properties that may favor progression of the disease.
In these studies we observed that an alteration in the normal ER/ER ratio takes
place within the human endometrium during estrogen-dependent endometrial disease
progression. The alteration always favored mitogenic signaling from ER, in both the
stromal and epithelial compartments of the endometrium, within hyperplastic samples
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Table 2.4. ER to ER Nuclear Ratio in Stromal and Epithelial Cells of Normal,
Hyperplatic, and Neoplastic Endometrial Biopsies.
.2
1
1
1
1.6
1
2
1
.71
1
1.43
1
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Table 2.5. ER to ER Nuclear Ratio in Stromal and Epithelial Cells of Normal,
Hyperplatic, and Neoplastic Endometrial Biopsies.
4.53
1
1
1
0.63
1
0.48
1
1.4
1
0.7
1
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compared to normal samples. This finding suggests that the ER ratio must stay within certain
boundaries to maintain a normal response to estrogens within the uterine microenvironment.
This data also correlates with recent findings of increased p160 coactivator expression in the
uteri of women with PCOS, who are likely to progress to endometrial hyperplasia and cancer,
suggesting that ERs will have the necessary tools to induce transcription in response to
estrogens (Gregory, et al. 2002). Additionally, Korach et al. noted that ERKO mice have an
exaggerated proliferative response to estrogens within the compartments of the uterus. The
data presented within this chapter is consistent with these observations, in that an alteration
of the ratio between the ERs leading to an abnormal increase of ER expression over that of
ER leads to increased cellular proliferation, as seen in hyperplasia, which is a precursor for
type-1 endometrial cancer. Moreover, this finding may provide a mechanism whereby the
epithelium overcomes the need for paracrine mediated factors, emanating from the stroma, to
stimulate growth. Furthermore, the data contained herein is consistent with the hypothesis
that ER is a modulator of ER within the human endometrium. Finally, in order to elicit the
mitogenic effects of ER within this tissue there is an alteration of the homeostatic balance
between the receptors in hyperplastic endometrial biopsies, a critical junction in estrogen-
mediated endometrial disease progression.
Taken together, the data presented within this chapter suggests that the alteration in
the ER/ER ratio seen in the hyperplastic endometrial tissue setting, which is a key step
toward estrogen-induced carcinogenesis within this tissue. This data also identifies the need
to further investigate the potential role of both receptor subtypes in the regulation of
endometrial epithelial cell proliferation and gene expression and will be addressed in
chapters III and IV of this dissertation.
Chapter III: Characterization of the Roles of the Estrogen Receptors Alpha and Beta
on Estrogen-Induced Gene Regulation
Abstract
Endometrial cancer is a major cause of morbidity and mortality in the western world.
The primary risk factor for development of this disease is unopposed endogenous and
exogenous estrogens. The mechanisms by which estrogen elicits its effects in the human
endometrium are not well known. Herein, we provide evidence consistent with the
hypothesis that Estrogen Receptor (ER)  is the primary receptor subtype involved in the
upregulation of estrogen-inducible genes using the placental alkaline phosphatase (ALPP)
gene as an example. Cytochemical and Quantitative-PCR (qPCR) for ALPP revealed that the
ER-selective agonist, Propylpyrazole triol (PPT), can induce ALPP message and activity,
indicating that ER is necessary to upregulate this gene. However, the ER-selective
agonist, Diarylpropionitrile (DPN), failed to upregulate ALPP message or product. We have
recently acquired an isogenic Ishikawa cell line, Ishikawa-3H12, which lack functional ER
expression. Isogenic derivatives of Ishikawa-3H12 that stably express a single ER subtype
have been constructed in order to complement the studies conducted with the ER agonists.
These studies revealed that ER, and not ER, is responsible for the upregulation of ALPP.
Further studies utilizing U0126 and LY294002, inhibitors of MAP-Kinase and (PI)3-kinase,
respectively, revealed that the upregulation of ALPP is at least in part due to these signaling
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pathways in this endometrial adenocarcinoma model system. Taken together, the data
suggests the existence of a membrane/cytoplasmic version of ER, and that its activation
results in the upregulation of ALPP via MAPK and (PI)3-kinase. Furthermore, ER activity
within the same compartment does not negatively regulate ALPP.
Introduction
Endometrial cancer is a major cause of morbidity and mortality in women and is the
most common gynecologic malignancy (Rose 1996). The American Cancer Society estimates
that 41,200 new cases will be diagnosed and 7,350 deaths will result from endometrial cancer
in the United States in 2007. The incidence of endometrial cancer, like most cancers, is
dependent on age. The median age of patients diagnosed with this disease is 63 years.
Seventy-five percent of women diagnosed with endometrial cancers are post-menopausal.
The predominant classic etiological factor associated with the development of
endometrial carcinoma is exposure of the endometrium to endogenous and/or exogenous
estrogens that are not modulated by progesterone (Rose 1996). Stimulation of the
endometrium with excess and unopposed estrogen can lead to hyperplasia, which increases
the risk of developing atypical hyperplasia and type 1 endometrial cancer (Montgomery et al.
2004). The physiologic effects of estrogens are mediated by two distinct transcription factors
known as the estrogen receptor (ER)  and . Currently, there are two pathways, classical
and non-classical, by which the receptor subtypes are known to elicit their actions. In the
well accepted classical pathway, the receptors are activated by ligand in the nucleus and in
turn influence gene activation by binding to DNA in the promoter of responsive genes and
recruiting coregulators which interact with the basal transcriptional machinery to induce
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transcription of responsive genes (Graumann and Jungbauer 2000; Pratt 1998; Pratt and Toft
1997; Robyr et al. 2000; Smith 1998; Smith and Toft 1993). The less well accepted, non-
classical pathway of ER action involves membrane/cytoplasmic forms of the ERs which are
activated by ligand and in turn activate various cytoplasmic signaling cascades, such as
(PI)3-kinase and MAP-Kinase to elicit transcription of estrogen responsive genes (Kim et al.
1998; Stoica et al. 2003). Although the mechanisms of ER action are known, their individual
contributions in the regulation of target genes within the human endometrium are not well
defined. Further evidence about the role of the two receptors has followed the development
of estrogen receptor knockout (ERKO) mice which allows the function of the individual
receptor subtypes to be evaluated.
ER knockout (ERKO) mice carry a null mutation within the ER gene, and were
the first model to show the phenotypic results of having only one receptor subtype. These
mice exhibit developed uteri containing the usual epithelial, stromal, and myometrial cell
types and endometrial and myometrial structures (Lubahn et al. 1993). However, the tissue
components were reported to be diminished in size and their cells were insensitive to natural
and synthetic estrogens. They fail to stimulate DNA synthesis and induce estrogen
responsive genes in response to pharmacologic doses of estrogen or the synthetic agonist,
diethylstilbestrol (DES), as is seen in wild-type littermates (Lubahn et al. 1993). This finding
suggests that ER is an important mediator of both normal cellular proliferation and
estrogen-mediated gene regulation within the rodent uterus.
Unlike their counterparts, ER knockout (ERKO) mice develop uteri with normal
epithelial, stromal, and myometrial cells and normal sized endometrium and myometrium
(Krege et al. 1998). The uteri of ERKO mice maintain their responsiveness to estrogens. In
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fact, these mice exhibit an increase in Ki-67 protein, a cell proliferation marker, and an
exaggerated proliferative response to 17-estradiol. These effects suggest that ER may be
able to serve some of the effects of ER in ERKO mice yet normally serves an important
role in modulating the effects of ER. ER may also provide an antiproliferative function in
the immature uterus (Walker and Korach 2004).
Distinguishing the functions of estrogen receptors  and  is crucial to understanding
the mechanisms of estrogen-related disease. Such knowledge may help to elucidate how cell
proliferation is normally regulated by ER and ER the endometrium and how
hypersensitivity to estrogens may contribute to endometrial carcinogenesis. To determine the
roles of each ER in the transcriptional response to estrogens we chose to use the placental
alkaline phosphatase (ALPP) gene, which is an estrogen-inducible gene whose product is
easily detected using a cytochemical assay (Littlefield, et al. 1990). We studied ALPP
induction in cells expressing ER or ER or neither. Additionally, we utilized two
commercially available highly specific agonists of the ER and ER, PPT and DPN,
respectively.
Materials and Methods
Cell culture. Ishikawa endometrial adenocarcinoma cells, an established endometrial
epithelial cancer cell line, were maintained in stromal medium (SM) consisting of a 1:1
mixture of Ham’s F12 (GIBCO™, Invitrogen Corp.) and M199 basic medium (Sigma)
supplemented with 5% bovine calf serum (BCS; Hyclone), 0.1%Mitoplus (BD Biosciences),
2µg/ml insulin (Sigma) and antibiotic/antimycotic (hereafter referred to as ABAM; source
(GIBCO™). Ishikawa-3H12, 3H12, 3H12, and 3H12/ cells were routinely maintained in
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DMEM-F12 (GIBCO™) culture medium supplemented with 5% fetal calf serum, 200mM L-
glutamine, and ABAM. Cells were transferred to steroid-free medium JAC-0.5 containing
1:1 F12/M199, ABAM, 0.5% charcoal-stripped fetal bovine serum (Hyclone), 0.25% ITS+™
(insulin-transferrin-selenium plus lipoic acid, Becton Dickinson), 0.1mM
phosphorylethanolamine (Sigma) and 2mM glutamine (GIBCO™) prior to hormonal
stimulation. The stromal medium and JAC 0.5 treatment media were phenol red-free. All
cultures described in this report were maintained at 37oC in a humidified atmosphere of 5%
CO2.
Alkaline phosphatase assay. On the day of the experiment, cells were seeded at a
density of 7x103 cells per well in a 96-well flat bottom microtiter plate (Costar) using stromal
medium (SM) for the Ishikawa cells, and DMEM for the Ishikawa-3H12 cells. Test
compounds were dissolved in ethanol and were diluted in JAC-0.5 medium (final
concentration of ethanol, 0.1%). After addition of compounds (200µl/well) cells were
incubated for 72 hours at 37oC in humidified air with 5% CO2.
At the conclusion of the experiment, the medium was removed from the microtiter
plates by inverting and shaking. 96-well plates, containing cells, were subsequently washed
twice by immersing each plate into one liter of 1x PBS (0.15M NaCl, 10mM sodium
phosphate, pH 7.4) (GIBCO™). Following the last wash, microtiter plates were blotted over
clean paper towels. Methanol (Mallinckrodt Chemicals) was then added to each well of the
plate and plates were placed at -70oC for 20 minutes and subsequently allowed to thaw at
room temperature for five minutes. Methanol was then removed by shaking, and the 96-well
plates, containing cells, were blotted over clean paper towels to remove residual methanol.
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To each well, 100µl of ALPP substrate [p-nitrophenyl phosphate, pNPP (Sigma) 0.24mM
MgCl2, and 1mM diethanolamine (pH 9.8)] was then added to the cells. Plates were
incubated at room temperature protected from light for one and a half to three hours.
Following incubation, the intensity of developed color product was determined by reading
the 96-well plates in a plate reader at 405nm.
Chromatin immunoprecipitation (ChIP) assays. Ishikawa cells were cultured in
steroid-free medium containing charcoal stripped fetal bovine serum (csFBS) and treated,
with either 10-8M 17-estradiol or vehicle (ethanol), for indicated timepoints. ChIP assays
using antibodies specific for acetylated histone H3 (Upstate), ER (Santa Cruz), or ER
(Santa Cruz) were performed. PCR was carried out using primers amplifying the putative
estrogen response elements (EREs), 1 and 2, located 1.9 kb and 2.2 kb upstream of the start
site of the ALPP gene, respectively. Cells were treated with 1% formaldehyde at room
temperature for 15 minutes. Pellets were collected and lysed in 400µl lysis buffer [1% SDS,
10 mM EDTA, 50 mM Tris (pH 8.0)] plus protease inhibitors for 10 minutes on ice. Cells
were then sonicated with 7 pulses of 3 seconds each using a Branson Sonifier 200 (Branson
Sonifier). Sonification produced chromatin fragments of approximately 600 basepair (bp).
Insoluble debris was removed by centrifugation and the soluble chromatin was diluted 2-fold
with dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris (pH 8.1),
and 167mM NaCl] plus protease inhibitors. 200µl of the diluted solution were precleared
with protein A agarose beads (Upstate Biotechnology) for 30 minutes at 4°C, to prevent non-
specific binding. In separate experiments, 800µl of the supernatant was incubated for 2 hours
at room temperature with antibodies against acetylated histone H3 (Upstate Biotechnology),
77
ER (Santa Cruz), or ER (Santa Cruz). 600µl of protein A agarose was added and the
mixture was incubated overnight at 4°C. The next day, beads were washed sequentially with
a low salt buffer [20mM Tris-HCl pH 8.0, 150mM NaCl, 0.1% Sodium Dodecyl Sulfate
(SDS), 1% Triton X-100, 2mM Ethylenediaminetetraacetic acid (EDTA)], a high salt buffer
[20mM Tris-HCl pH 8.0, 500mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA], a LiCl
buffer [20mM Tris-HCl ph 8.1, 250mM LiCl, 500mM NaCl, 1% NP-40, 1% Deoxycholate,
2mM EDTA], and a TE buffer [10mM Tris-HCl pH 7.5, 1mM EDTA]. Immunocomplexes
were eluted from protein A agarose beads with 250µl of elution buffer [1% SDS, 0.1M
NaHCO3] while rocking at room temperature for 15 minutes. Immunocomplexes were heated
at 65°C for 4 hours to dissociate the DNA/protein cross-links. Organic extractions were
carried out with phenol:chloroform:isoamyl alcohol (GIBCO™). DNA was precipitated
using sodium acetate and resuspended in 50 µL water. 200µl of diluted soluble chromatin
processed in the same way but without immunoprecipitation was termed “input DNA”. PCR
reaction conditions used to detect precipitated DNA fragments were as follows: 95oC-12
minutes (activation of the polymerase), and cycled 35 times at, 94oC-1 minute, 60oC-1
minute, 72oC-1 minute. The primer sequences were as follows: ERE-1 forward, 5’-TCTCG
ACACC AGAAC ACAGC-3’; ERE-1 reverse, 5’-TACAG ATGCA TTTGG GTGA-3’;
ERE-2 forward, 5’-ACCTG AGCTG CCTTT CTGAG-3’; ERE-2 reverse, 5’-CGGGT
TTAAA TCAGG GAGAA-3’. PCR products were separated by electrophoresis on agarose
gels, and visualized.
RNA and quantitative real time PCR. Total cellular RNA was prepared from cells
using the SV Total RNA Isolation kit (Promega Corp.). Total cellular RNA was used to
produce first strand cDNA during the initial qPCR cycle. qPCR reactions were carried out
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using Taqman universal PCR mastermix in the ABI PRISM 7700 system (Applied
Biosystems) using the following reaction conditions: 48oC-30 minutes (cDNA synthesis);
95oC-10 minutes (Activation of the polymerase); and 35 cycles at 95oC-15 seconds, and
60oC-1 minute. The real time PCR probes used for this system were constructed with a
reporter dye, 6-FAMTM or 6-TETTM, on the 5’ end and a black hole quencher, TAMRATM, on
the 3’ end. The following primers and probe sequences were constructed in the
Oligonucleotide Core Facility in the Department of Pathology and Laboratory Medicine for
use in this assay: Placental alkaline phosphatase (ALPP) mRNA forward, 5’-GCT TCT TCC
TCT TCG TGG A-3’; ALPP reverse 5’-TCT CAG TCAGTG CCC GGT A-3’; and ALPP
Probe 5’-6- FAMTM -CA TGA TGA CCA TGG TCG ATG CGA- TAMRATM -1-3’; -Actin
forward 5’-GGT CAT CAC CAT TGG CAA TG-3’, -Actin reverse 5’-TAG TTT CGT
GGA TGC CAC AG-3’, -Actin Probe 5’-6- TETTM -CA GCC TTC CTT CCT GGG CAT
GGA- TAMRATM -1-3’. -Actin mRNA levels were used to correct for RNA loading.
Immunodetection of hormone receptors. Cultures were washed in cold saline buffer
and scraped in 52µl/cm2 of modified RIPA buffer [50mM Tris-HCl, pH 7.4; 150mM NaCl; 1
mM EDTA; 1% NP-40 detergent; 0.25% sodium deoxycholate; 1mM
phenylmethanesulphonylfluoride (PMSF); 1µg/ml each of aprotinin, leupeptin, pepstatin;
1mM sodium orthovanadate and 1mM sodium fluoride]. The resuspended cells were
transferred to a 1.5ml microcentrifuge tube and incubated on ice for 30 minutes, then
centrifuged at 13,000xg for 30 minutes. The supernatants were assayed for total protein
concentration using a bicinchonic acid assay (Pierce Chemical Co.). Proteins in the cell-free
extracts were separated by SDS-PAGE in 10% polyacrylamide and electrotransferred onto a
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nitrocellulose membrane. TBS/0.1% Tween-20 buffer [20mM Tris-HCl, pH 7.6; 73 mM
NaCl; and 0.1% Tween-20] was used for all steps of the immunodetection and each step was
preceded by three 5-minute washes at room temperature. Blocking of non-specific signal was
achieved in 5% nonfat dry milk for 1 hour at room temperature. The blot was incubated
overnight at 4ºC with primary antibody diluted 1:1000 in 5% BSA-TBS/0.1% Tween-20,
then exposed to secondary antibody linked to horseradish peroxidase (Amersham) [1:2000 in
5% non fat dry milk in TBS/0.1% Tween-20] for 1 hour at room temperature. For protein
detection, the blot was incubated in a luminol substrate (Pierce) for 5 minutes, covered in
plastic wrap and exposed to X-ray film. Primary antibodies used were: anti-estrogen receptor
 mouse monoclonal [1:1000 dilution; Cell Signaling Technologies, Inc.], anti-estrogen
receptor  rabbit polyclonal [1:1000 dilution; Upstate].
Retrovirus production and cell line construction. ESR1, the human gene encoding the
estrogen receptor  protein was obtained from the laboratory of Dr. Donald P. McDonnell at
Duke University. This gene cDNA was encoded within the pV16 expression vector
(Clontech). The ESR1 gene was excised from pV16 by digesting with the EcoR1 restriction
enzyme (New England Biolabs). The resulting digest was electrophoresed on agarose to
separate the digested ESR1 gene fragment from the empty pV16 vector. The desired
fragment was purified with Gene Elute minus ethidium bromide (Sigma) and subsequently
ligated into the multiple cloning site of EcoR1 digested pQXCIN, a retroviral backbone with
a neomycin resistance marker (BD Biosciences). Competent bacteria were transformed with
the ligated pQXCIN-ER constructs and grown on Luria Miller Agar plus ampicilian culture
plates. Clones were picked and grown in Luria Broth (LB) media plus ampicilian. DNAs
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were then isolated from the bacteria and digested with the Eco R1 restriction enzyme to
ensure that the clone contained the cDNA insert. Following the identification of positive
clones digests with the BGL II restriction enzyme (New England Biolabs) were conducted to
ensure proper orientation of the gene cDNA sequence within the pQXCIN backbone.
Following identification of properly oriented constructs, large scale preparations were
conducted followed by DNA sequencing to ensure fidelity of the cDNA sequence.
The full length ESR2, the human gene encoding the estrogen receptor  protein was
obtained from the laboratory of Dr. Sohaib Khan in the Department of Cell Biology at the
University of Cincinnati. The ESR2 DNA was encoded on the pcDNATM3.1 expression
vector. Sequencing was carried out to ensure that this DNA was the full-length ER cDNA
and to ensure fidelity of the construct. The ESR2 sequence was amplified from the vector
using primers, Forward- 5’-CCC GGA TCC ATG GAT ATA AAA AAC TCA C-3’ and
Reverse- 5’-CCC GGA TCC TCA CTG AGA CTG AGA CTG TGG GTT C-3’, which
placed Bam H1 restriction sites and Kozak fragments at the 5’ and 3’ ends of ESR2. PCR
reactions were run with Proof-StartTM Taq Polymerase (Qiagen) at 95oC-15 minutes
(activation of the polymerase), and cycled at 94oC-30 seconds, 58oC-30 seconds, and 72oC-
1.5 minutes for 32 cycles. PCR products were electrophoresed on agarose and excised. The
ESR2 gene cDNA was purified with Gene Elute minus Ethidium Bromide (Sigma) and
subsequently digested with the Bam H1 restriction enzyme (New England Biolabs). The
desired fragment was ligated into the multiple cloning site of Bam H1 digested pQXCIP, a
retroviral backbone with a puromycin resistance marker (BD Biosciences). Competent
bacteria were transformed with the ER-pQXCIP construct and grown on Luria Miller Agar
(GIBCO™) culture plates. Clones were picked and grown in Luria Broth (LB) media plus
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ampicilian. DNAs were prepared and digests with Bam H1 were carried out to identify
clones containing the cDNA insert. Following identification of positive clones, digests with
BGL II and Eco RV restriction enzymes (New England Biolabs) were conducted to ensure
proper orientation of the gene sequence within pQXCIP. Following identification of properly
oriented constructs, DNA sequencing was carried out to ensure fidelity of the sequence.
As described above, the ESR1 and ESR2 DNA sequences were subcloned into the
retroviral expression vectors pQCXIN and pQCXIP (BD Biosciences), respectively.
Vesicular Stomatitis Virus-G pseudotyped, replication-incompetent retroviruses were
produced by transient three-plasmid transfection into HEK-293T host cells (Soneoka, et al.
1995). Retroviruses were pelleted and resuspended in 1ml 1X Hanks Buffered Saline
Solution (HBSS) plus Ca+, Mg+. Recipient cells, Ishikawa-3H12, were plated at a density of
50,000 cells and infected with the retroviruses preparations (1X-450uL or .1X-45ul) in the
presence of 8µg/ml hexadimethrine bromide (Sigma) for 6 hours. This treatment was
repeated the next day. Starting on day 3, transduced cells and a mock-infected control were
treated with Neomycin (400µg/ml), pQXCIN-ER, or Puromycin (400ng/ml), pQXCIP-ER,
for 10 days. Following this interval, the control uninfected cells died and survivor cells in
the infected culture were amplified and passed. Cells expressing ER were named 3H12
and were used as a population, while those expressing ER were named 3H12 and were
cloned revealing several clones expressing various levels of ER. All studies conducted
within this dissertation were completed using 3H12 clone 13. A third cell line expressing
both ER and ER, 3H12, was constructed using the 3H12 clone 13 cells and re-infecting
them with the pQXCIN-ER retroviral preparations. The cells were then subjected to
selection with neomycin for 10 days. Survivor cells were amplified and used as a population.
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Results
Cytochemical assay of placental alkaline phosphatase activity in estrogen-stimulated
Ishikawa cells and Ishikawa-3H12 cells. To elucidate the roles of the two ERs on gene
regulation we chose to use the placental alkaline phosphatase (ALPP) gene because the
activity of the enzyme it encodes can be detected easily with a colorimetric cytochemical
assay (Littlefield et al. 1990). Both conventional Ishikawa cells (ER expressing) and its
derivative cell line Ishikawa-3H12 (null ER background) were treated with 17-estradiol in
concentrations ranging from 10-14 M to 10-5 M and ALPP activity was determined in the
treated cells. The conventional Ishikawa cells responded to the 17-estradiol treatment in a
dose-dependent manner with the highest level of activity observed at 10–8 M (10nM). In
contrast, the Ishikawa-3H12 cells, which do not express functional ER or ER, did not
respond to treatment with estrogen indicating that induction of ALPP expression depends on
liganded ER, or ER, or both (Figure 3.1).
Quantitative-PCR analysis of ALPP message in estrogen-stimulated Ishikawa cells.
In an effort to demonstrate that the increase in alkaline phosphatase activity that was
observed in estrogen-treated Ishikawa cells was the result of increased transcriptional
activation, a quantitative real-time PCR (qPCR) was developed to detect placental alkaline
phosphatase mRNA. Cells were grown in 10cm tissue culture plates and treated for 72 hours
with 10-8 M 17-estradiol +/- the powerful antiestrogen ICI 182780 (10-7 M), which blocks
both the ER and ER, or the highly specific ER antagonist MPP (10-6 M). RNA was
isolated using a Qiagen RNeasy kit and qPCR reactions were completed at the
Oligonucleotide Synthesis Core Facility in the Department of Pathology and Laboratory
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Figure 3.1. Induction of Alkaline Phosphatase Activity in Ishikawa, and not
Ishikawa-3H12 Cells, by 17-Estradiol. Ishikawa and IK 3H12 were seeded at 7000
cells/well and treated with increasing concentrations of 17-estradiol (10-14M to 10-5M)
for 72 hours. ALPP activity in the IK 3H12 cells is not upregulated due to the lack of
either estrogen receptor.
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Figure 3.2. The Potent Anti-Estrogen, ICI 182780, Inhibits Upregulation of
Alkaline Phosphatase Activity by Estrogen. Ishikawa and IK 3H12 were seeded at
7000 cells/well and treated with increasing concentrations of 17-estradiol + ICI
182780 for 72 hours. ALPP activity in the IK 3H12 cells is not upregulated due to the
lack of either estrogen receptor. See Figure 3.1 to compare the reduction in activity. *
indicates p<0.05.
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Medicine on an ABI Prism 7700. Treatment with 10-8M 17-estradiol induced a 14-fold
induction in ALPP message, but this induction could be inhibited with the total ER inhibitor
ICI 182780 or the ER specific antagonist MPP (Figure 3.3). This data indicates that
estrogen causes transcriptional upregulation of ALPP by an ER mediated process.
Furthermore, studies using MPP, the ER specific antagonist showing that the ALPP
induction by 17-estradiol is completely abrogated, indicates that ER is the obligatory
receptor for upregulation of the ALPP gene.
Upregulation of ALPP by the ER selective agonists, PPT. PPT and DPN, specific
agonists of the ER and , respectively, provided useful tools for the elucidation of the
estrogen receptors roles. Studies in which conventional Ishikawa cells were treated with the
ER selective agonist, PPT, showed that the message and activity of ALPP was increased
significantly above the levels seen in cells treated with vehicle (Figure 3.4). In contrast,
conventional Ishikawa cells treated with the ER selective agonist, DPN, did not show an
inhibition of basal levels of ALPP activity, and did not have significant levels of ALPP
activity or message when compared with cells treated only with the vehicle (Figure 3.3).
However, we did note that concentrations above 10-8M DPN did increase ALPP activity.
This increase is directly attributed to the ability of DPN to stimulate ER at higher doses.
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Figure 3.3. qPCR Reveals Inhibition of ALPP Message in Ishikawa Cells by ICI
182780 and MPP. Cells were treated with 10-8M 17-estradiol , +/- 10-7M ICI 182780
(the total ER inhibitor) or 10–6M MPP (ER Inhibitor) for 72 hours. RNA was extracted
and qPCR was performed for ALPP and -Actin.
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Figure 3.4. Signaling Through ER is Involved in the Induction of ALPP Activity.
Ishikawa cells were seeded at 7000 cells/well and treated with 10-8M 17-estradiol or
increasing concentrations of the ER agonist, PPT (10-9M to 10-6M), for 72 hours.
ALPP activity was determined by colorimetric assay. The results show that ALPP
activity is upregulated at least in part, by ER. * indicates p<0.05.
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Figure 3.5. ER is Not Involved in Increased ALPP Activity. Ishikawa cells were seeded
at 7000 cells/well and treated with 10-8M 17-estradiol or increasing concentrations of the
ER agonist, DPN (10-9M to 10-6M), for 72 hours. ALPP activity increases as the
concentration of DPN increases. However, we have shown that this effect is due to DPN
binding the ER by using the ER inhibitor, MPP. Therefore, ALPP does not appear to be
upregulated by ER. * indicates p<0.05.
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Figure 3.6. ALPP Message is Increased in Ishikawa cells by 17-Estradiol and PPT.
Ishikawa cells were treated with 10-8M 17-estradiol, 10-8M PPT, or 10-8M DPN +/- 10-7M
ICI 182780 for 72 hours. RNA was extracted and qPCR was performed for ALPP and -
Actin. ALPP message is increased in response 17-Estradiol, and PPT, but not DPN. The
increase can also be inhibited by ICI 182780, which indicates that upregulation is in fact
mediated through the estrogen receptor(s).
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Construction of cell lines expression ER, or ER or both by stable transfection of the
ER subtypes into Ishikawa cells lacking functional ER activity. In an effort to understand the
individual contributions of the ERs in the regulation of the estrogen-inducible ALPP we
needed a model system in which cells express one or both receptor subtypes. The Ishikawa-
3H12 cell line, which lacks functional expression of either ER or ER, was stably
transduced using retroviral vectors containing ER, or ER (3H12, 3H12). ER,
expressing cells were selected with neomycin for 10 days and subsequently used as a
population. In contrast, ER cells were selected with puromycin for 10 days and cloned,
which revealed several clones with varying receptor protein expression levels. The studies
contained herein utilized 3H12 clone-13, because its expression of ER was similar to that
found in conventional Ishikawa cells. The Ishikawa-3H12 clone-13 was transduced with
retroviral vectors containing ER used to produce a third cell line expressing both receptor
subtypes (3H12). For the purpose of these studies, the 3H12 cell line was used as a
population. The results of a Western immunoblot analysis using antibodies against the ERs
reveal the expression phenotypes of the newly created cell lines as compared against
Ishikawa cells (Figure 3.4).
Regulation of ALPP by 17-estradiol in Ishikawa cells and clones 3H12, 3H12, and
3H12. To elucidate the roles of the two estrogen receptors on ALPP gene regulation we
utilized the cell clones constructed to express a single ER. Ishikawa, Ishikawa-3H12, 3H12,
and 3H12 cells were treated with 17-estradiol ranging from 10-14 M to 10-5 M and then
assayed colorimetrically to detect ALPP activity (Figure 3.8 a-d). As shown earlier (Figure
3.1), ALPP activity is upregulated in Ishikawa cells, but not in 3H12 cells. Treatment of the
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Figure 3.7. Protein Expression of ER Constructed Cell Lines. 30µg of total cell protein
from Ishikawa, 3H12, 3H12, 3H12, and 3H12 populations were loaded and run on a
SDS-page gel. Antibodies against ER, ER, and GAPDH were used to determine protein
expression within each cell line. (MCF-7 cell lysates were used as a positive control and
are not shown.)
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Figure 3.8. Induction of Alkaline Phosphatase Activity in Stable ER Expressing
Cell Lines. Ishikawa, 3H12, 3H12, and 3H12 cells were seeded at 7000 cells/well
and treated with increasing concentrations of 17-estradiol (10-14M to 10-5M) for 72
hours. A dose response in ALPP activity in is restored in the 3H12, but not the
3H12 cells.
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3H12, 3H12 revealed gene induction by estrogen in the 3H12 but not the 3H12. From
this we conclude that ER is the primary estrogen receptor responsible for the upregulation
of ALPP. In cells expressing ER (3H12) we detected a high background of ALPP activity,
but ALPP activity did not respond to treatment with 17-estradiol (Figure 3.8 d).
Search for EREs in the promoter region of the placental alkaline phosphatase gene.
As shown above, placental alkaline phosphatase is an easily measured estrogen-inducible
gene. Most estrogen responsive genes contain one or more estrogen response elements (ERE)
in their promoter regions and it is at these sites that estrogen receptors bind to DNA to exert
their transcriptional activation role. The classic ERE was derived from the Xenopus laevis
vitellogenin A2 promoter and was found to be composed of two palindromic half-sites
separated by three nucleotides, 5’AGGTCAnnnTGACCT3’, where n can be any nucleotide
(Klein-Hitpass et al. 1986). More recently, a new subclass of EREs have been identified and
are thought to be derived from Alu sequences (Norris et al. 1995).
Although placental alkaline phosphatase is a gene of choice for studying the
estrogenic activity of various compounds in the endometrium, the regulatory region of this
gene has not been described. To pursue this research objective, it was essential to first better
characterize the promoter region of ALPP, specifically to identify ERE’s present within it.
To accomplish this goal, the Dragon ERE Finder program (http://sdmc.lit.org.sg/ERE-
V2/index) was used to locate putative EREs within the 5’ flanking region of the ALPP gene.
The entire 5” flanking region of the ALPP gene was entered and the program identified two
putative EREs, which were named ERE-1 and ERE-2. These elements are located 1973, and
2213 base pair, respectively, upstream of the TATA start site for ALPP. The sequence for
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Figure 3.9. Schematic Representation of the Putative EREs Found in the 5’
Flanking Region of ALPP. The Dragon ERE Finder software located two putative
EREs, located on the complimentary DNA strand 1973 basepair (ERE-1; TG-
GAACA-AGA-CACCC-TG) or 2213 basepair (ERE-2; GT-TGCCA-CCT-TGACC-
CT) upstream from the TATA start site in the 5’ flanking region of the ALPP gene.
TATAERE-1ERE-2
Alkaline Phosphatase
1973 bp
2213 bp
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ERE-1 is TG-GAACA-AGA-CACCC-TG and that for ERE-2 is GT-TGCCA-CCT-TGACC-
CT. Both putative response elements were identified on the reverse compliment strand and
are not considered classic EREs (Figure 3.9).
Effect of estrogen on histone acetylation of EREs in the ALPP promoter region.
Specific acetylation of histones associated with the promoter region of genes has been
correlated with increased transcriptional activity. To understand if the putative response
elements (ERE-1 and ERE-2) discovered above are in transcriptionally active regions of the
genome in estrogen-treated cells we utilized a chromatin immunoprecipitation assay (ChIP)
with anti-acetylated histone H3 antibodies. This technique exploits protein-DNA interactions
to isolate and characterize specific sequence binding and was used here to evaluate the
acetylation status of histone H3 in the newly identified estrogen response elements in the
promoter regions of the ALPP gene. We found that both ERE-1 and ERE-2 primers
amplified DNA when immuno-duplexes containing acetylated histone H3 were precipitated
from Ishikawa cells, indicating that both response elements are associated with nucleosomes
containing acetylated histones (Figure 3.10). This suggests the presence of a more open
chromatin conformation, and therefore an active gene. We also evaluated acetylation of
histone H3 in the conventional Ishikawa cells in response to 17-estradiol. In this set of
experiments we observed a rapid acetylation of histone H3 within 45 minutes indicating that
both sites are located in transcriptionally active regions of the gene (Figure 3.10).
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Figure 3.10. ChIP Assay Showing That ERE-1 and 2 are Located Within
Transcriptionally Active Regions of the Genome. Chromatin from Ishikawa cells
growing in 4% csFBS was crosslinked, sheared, immunoprecipitated with non-specific
IgG or Anti-Ac-Histone H3 antibody. A control with no antibody was also added. PCR
was carried out on the purified DNA and the resulting reactions were resolved on a 2%
agarose gel stained with ethidium bromide (shown in reverse contrast). G6PD 6.4K is an
area of the genome known to be associated with acetylated-histone H3, and is therefore
used as a positive control.
G6PD 6.4K
ERE-1
ERE-2
Con. IgG Ac-H3
Input Con. Input IgG Input Ac-H3
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Non-classical ER Signaling
Activation of MAP-Kinase and (PI)3-Kinase in the Ishikawa cell line by 17-
estradiol. In an effort to determine whether 17-estradiol upregulates ALPP expression via
cytoplasmic signaling cascades we evaluated the ability of estrogen to induce
phosphorylation (activation) of regulatory proteins in the MAP-Kinase and (PI)3-kinase
pathways. Ishikawa cells were treated with 10-8M 17-estradiol for specific time intervals
every 15 minutes for the first hour and then at 3, 6, 12, and 24 hours. The cells were
harvested and cell lysates were subjected to Western immunoblot analysis using antibodies
against both the native (unphosphorylated) and activated (phosphorylated) MAPK and (PI)3-
kinase pathway proteins. The results revealed that treatment of conventional Ishikawa cells
with 17-estradiol lead to a rapid and biphasic activation of the MAPK pathway (Figure
3.11). Furthermore, the (PI)3-kinase pathway is constitutively activated in the Ishikawa cells
due to the loss of the key regulator of the pathway, PTEN. However, treatment with 17-
estradiol leads to a further increase in phosphorylation of Akt as determined by Western
immunoblot analysis (Figure 3.12).
Effects of MAP-Kinase and (PI)3-Kinase inhibitors on the upregulation of ALPP by 17-
estradiol. Commercially available inhibitors of the MAPK (U0126) and (PI)3-K
(LY294002) pathways provide useful tools for elucidating the roles of these cytoplasmic
signaling pathways in assays of their biological function. Herein, studies evaluated the ability
of 17-estradiol to upregulate ALPP expression in the presence of U0126 (10µM) or
LY294002 (10µM) (Figure 3.13). Treatment of Ishikawa cells with 10µM U0126 (Figure
3.13) or LY294002 (Figure 3.14) significantly reduced the upregulation of ALPP mRNA by
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Figure 3.11. MAP-Kinase Induction by 17-estradiol. Ishikawa cells were treated
with 10-8M 17-estradiol for the indicated times. 30µg of total cell protein from the
cells was loaded and run on a SDS-page gel. Antibodies against phosphorylated
MAPK (PP44/42) or total MAPK (44/42), a loading control, were used to determine
protein expression. This cell line showed a rapid response to treatment, which led to a
biphasic activation of the MAPK pathway.
PP44/42
44/42
C 15m 30m 45m 60m 3h 6h 12h 24h
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Figure 3.12. (PI)3-Kinase Induction by 17-estradiol. Ishikawa cells were treated
with 10-8M 17-estradiol for the indicated times. 30µg of total cell protein from the
cells was loaded and run on a SDS-page gel. Antibodies against phosphorylated Akt
(P-Akt) or total Akt (Pan-Akt), a loading control, were used to determine protein
expression. This cell line showed a rapid response to treatment, which led to an
increase in the phosphorylation of Akt.
P-Akt
Pan-Akt
C 15m 30m 45m 60m 3h 6h 12h 24h
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Figure 3.13. Inhibition of 17-Estradiol Induced ALPP Activity by a PI3-K
Inhibitor. Ishikawa cells were seeded at 7000 cells/well and treated with increasing
concentrations of 17-estradiol (10-14M to 10-5M) +/- 10µM of the PI3-Kinase inhibitor,
LY294002 for 72 hours. Inhibition of the PI3-K pathway prevents upregulation of ALPP
in response to 17-estradiol. * indicates significant change (p<0.05) as compared to
estrogen only treated cells.
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Figure 3.14. Inhibition of 17-Estradiol Induced ALPP Activity by a MAP-K
Inhibitor. Ishikawa cells were seeded at 7000 cells/well and treated with increasing
concentrations of 17-estradiol (10-14M to 10-5M) +/- 10µM of the MAP-Kinase
inhibitor, U0126 for 72 hours. Inhibition of the MAP-K pathway ablates 17-estradiol’s
ability to upregulate ALPP activity. * indicates significant change (p<0.05) as compared
to estrogen only treated cells.
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Figure 3.15. qPCR Reveals Inhibition of ALPP Message by PI3-K and MAP-K
Inhibitors. Ishikawa cells were treated with 10-8M 17-estradiol +/- 10µM LY294002
or 10µM U0126 for 72 hours. RNA was extracted and qPCR was performed for ALPP
and -Actin
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17-estradiol. Since 10µM U0126 and LY294002 are considered somewhat cytotoxic, as
they slightly reduce the number of Ishikawa cells as compared to nontreated cells, the
cytochemical assay may not represent the best measure of the effects of both compounds on
ALPP activity and/or expression. However, qPCR revealed that upregulation of ALPP
message was significantly inhibited by both U0126 and LY294002 (Figure 3.15).
Discussion
The roles of the estrogen receptors  and  in signaling within the human
endometrium are not completely understood. However, evidence accumulated in estrogen
receptor knockout (ERKO) mice suggests that the receptor subtypes have different roles in
the uteri of mice. ER is a stimulator of proliferation and estrogen-responsive gene
expression, while ER’s actions are largely inhibitory. The activity of ER has been studied
extensively in the human breast, and these results have been shown to parallel the findings in
the mouse models. However, the role of ER in the breast is less well understood. As the
basis for this study, we hypothesized that ER is stimulatory and ER is inhibitory with
regard to gene regulation in the human endometrium.
Studies described herein were undertaken to understand the individual roles of the
receptors in a human endometrial epithelial cell model system. We decided to use the easily
measured estrogen-inducible alkaline phosphatase gene as an example of an ER regulated
gene product (Littlefield et al. 1990). Utilizing specific agonists of the ER  and ER, we
were able to show that signaling through ER but not ER, lead to an upregulation in the
activity of the ALPP gene product. Furthermore, studies using cell lines constructed to
express either ER or ER showed results comparable to those with agonists of the two
104
receptors. The results support our hypothesis that ER is stimulatory with regard to induction
of this gene product. Our results show that regulation through ER is not stimulatory,
although they cannot support, nor disprove, the second portion of the hypothesis, which was
ER is inhibitory with regard to regulation of this gene.
To understand if ER is inhibitory with regard to ALPP expression we needed to
understand how the gene is regulated. A search for estrogen response elements (EREs) in the
ALPP 5’ flanking region identified two possible non-traditional elements (ERE-1 and ERE-
2), which are located 1923 and 2213 base pair upstream of the start site for ALPP
transcription, respectively. ChIP assays showed acyelation of histone H3 around the two
putative EREs. However, ChIP assays using antibodies against the ERs failed to
immunoprecipitate DNA encoding ERE-1 or 2. Despite these finding, the classic ER pathway
cannot be ruled out, as ERE-1 and ERE-2 may not properly show the regulatory sequences
within the promoter. The inability to confirm this pathway in the upregulation of ALPP may
also result from a signal level which is below our threshold of detection.
Recent literature suggests that 17-estradiol has other effects that cannot be explained
by the ligand-dependent mechanism due to their rapid onsets (Kato et al. 1995; Song et al.
2002; Voegel et al. 1998; Watson et al. 1999). Many of these effects, deemed non-classic,
have been linked to cell-surface forms of ER, which are thought to resemble nuclear ER
(Kato et al. 1995; Song et al. 2002; Voegel et al. 1998; Watson et al. 1999). There is a body
of evidence that links estrogen cell surface receptors and activation of the mitogen activated
protein kinase (MAPK) and phosphatidylinositol (PI)3-kinase signaling cascades (Song et al.
2002; Song et al. 2005; Stoica et al. 2003). These non-classic actions of the ER could explain
a direct connection between exposure to estrogen and stimulation of anti-apoptotic/pro
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cellular proliferation pathways that have been strongly implicated in carcinogenesis. Since
studies looking for liganded ER binding to ERE’s in the ALPP gene promoter were
inconclusive, we decided to use alternative methods to evaluate whether or not non-classic
actions of the ER’s were involved in the upregulation of the estrogen-inducible ALPP gene.
We found that treatment of the Ishikawa cells with 17-estradiol led to a rapid activation of
MAPK. Furthermore, although the (PI)3-kinase pathway in the Ishikawa cell model system is
constitutively activated due to the loss of the PTEN gene, treatment with 17-estradiol led to
a further increase in activity of the (PI)3-kinase pathway. Inhibitors of MAPK and (PI)3-
kinase, U0126 and LY294002, respectively, both prevented estrogen-induced upregulation of
ALPP message.
We have presented evidence that is consistent with the hypothesis that ER induces
expression of an estrogen-regulated gene in the human endometrium. Furthermore,
upregulation of the estrogen-inducible gene, ALPP, occurs at least in part through the
activation of the MAPK and (PI)3-kinase pathways in response to treatment with 17-
estradiol. This latter finding was surprising and strongly supports the existence of membrane
and/or cytoplasmic forms of the estrogen receptors. Although, we were unable to
demonstrate that ER is exerts an inhibitory function on the ALPP gene product, we can
conclude that cytoplasmic forms of ER are not inhibitory with regard to ALPP induction.
Chapter IV: Characterization of the Roles of the Estrogen Receptors  and  on
Proliferation of Endometrial Adenocarcinoma Cells
Abstract
Endometrial cancer is the most common gynecologic malignancy and is a major
cause of morbidity and mortality in women in the Western World. The American Cancer
Society estimates that 41,200 new cases will be diagnosed and 7,350 deaths will result from
endometrial cancer in the United States alone in 2007. Unopposed estrogen exposure is the
primary etiologic risk factor for developing this disease. However, the carcinogenic effects of
estrogen and its receptors are not well defined within the human endometrium. The principal
goal of this study is to understand the individual roles of the estrogen receptors (ERs)  and 
in the proliferation of endometrial epithelial cells. To achieve this goal, we utilized two
specific agonists of ER and ER, Propylpryazole-triol (PPT) and Diarylpropionitrile (DPN),
respectively. Treatment with PPT, DPN, and 17-estradiol significantly increased
proliferation of Ishikawa but not of Ishikawa-3H12 cells, an isogenic cell line that lacks
functional ER and ER expression. These results indicate that estrogen receptors are
involved in estrogen-induced proliferation of Ishikawa endometrial epithelial cells.
Furthermore, we developed cell lines which stably express the ER subtypes individually
(3H12 and 3H12) in the derivative of the Ishikawa-3H12 cell line. Compared to the
parental cell line, in the absence of added 17-estradiol, 3H12 cells showed a 103%
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increase in proliferation while 3H12 cells revealed a 45% decrease in growth. Moreover,
BrdU incorporation studies showed that 3H12 cells had a significantly reduced S-phase
population as compared against parental 3H12 cells. Treatment of both the 3H12 and
3H12 cells with 17-estradiol revealed significant increases in proliferation in response to
estrogen treatment. Despite this observation, 3H12 cells never reached levels of
proliferation seen in the parental cell line, suggesting that ER-mediated proliferation in
response to 17-estradiol is modest when compared to proliferation mediated by ER. Taken
together, these data strongly correlate with the findings in the breast and ovary, implicating a
lack of effect or a protective role for ER in estrogen induced proliferation.
Introduction
Endometrial cancer is a major cause of morbidity and mortality in the United States.
Exposure to unopposed estrogens is the primary etiologic risk factor associated with
increased proliferation of epithelial cells leading to the development of endometrial
hyperplasia and atypical hyperplasia. Atypical hyperplasia is often treated with progestin’s to
counteract the effects of estrogen or with hysterectomy (Jadoul and Donnez 2003). Without
treatment, twenty-five percent of women with atypical hyperplasia will develop type-1
endometrial cancer (Kurman et al. 1985). Although the primary risk factor for the disease has
been known for at least two decades, the precise mechanism of estrogen-induced
carcinogenesis in this tissue has not been clearly elucidated.
The physiologic effects of estrogens are mediated by two distinct transcription factors
known as the estrogen receptor (ER)  and  (Enmark et al. 1997; Green et al. 1986; Kuiper
et al. 1996; Menasce et al. 1993). The estrogen receptor  and  genes share significant
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homology. Despite the homology between these receptors, two different chromosomes
encode them, which rules out the possibility that they are splice variants (Enmark et al. 1997;
Kuiper et al. 1996; Menasce et al. 1993). There is remarkable conservation of the DNA-
binding domain (DBD) between the two estrogen receptors, which suggests that they should
be able to bind similar sequences within the promoters of estrogen-induced genes. The least
conserved domain, when comparing the two ER subtypes, is the ligand-binding domain
(LBD), which has 55% homology, suggesting that the receptors bind ligands with different
affinities. ER also lacks an efficient activating function-1 (AF-1) region, which influences
its interaction with coactivators that affect ligand responsiveness of the receptor (Hall and
McDonnell 1999).
Although the exact roles of the receptor subtypes are not known in the human
endometrium, evidence accumulated using estrogen receptor knockout (ERKO) mice has
provided plausible roles for each receptor in the human uterus. ERKO mice, which only
express ER, developed hypoplastic uteri that were insensitive to 17-estradiol, suggesting
that ER is an important mediator of both cellular proliferation and estrogen mediated
signaling within this rodent tissue. On the other hand, the increased cellular proliferation and
exaggerated response to 17-estradiol seen in ERKO mice, which express only ER,
suggest that ER may play an important role in modulating the effects of ER and may also
provide an antiproliferative function within the uterus (Walker and Korach 2004).
Since estrogen is extremely important in the development of endometrial cancer, it is
imperative to understand the contribution of the subtypes of estrogen receptor in the initiation
and progression of the disease. Most endometrial cell lines express both ER subtypes,
making it difficult to elucidate the individual contributions of each receptor within these
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cells. In this study the specific contributions of the individual ER subtypes were elucidated in
Ishikawa cells, a moderately differentiated endometrial adenocarcinoma cell line, utilizing
commercially available highly specific agonists of the two ER’s. Additionally, we used the
Ishikawa-3H12 cell line, an isogenic cell line that lacks functional expression of the ERs, to
construct separate endometrial adenocarcinoma cell lines that express ER, ER, or both ER
subtypes.
Materials and Methods
Cell culture. Ishikawa endometrial adenocarcinoma cells, an established endometrial
epithelial cancer cell line, were maintained in stromal medium (SM) consisting of a 1:1
mixture of Ham F12 (GIBCO™) and M199 basic medium (Sigma) supplemented with 5%
bovine calf serum (BCS; Hyclone), 0.1% Mitoplus (BD Biosciences), 2µg/ml insulin
(Sigma) and antibiotic/antimycotic (hereafter referred to as ABAM; source (GIBCO™).
Ishikawa-3H12, 3H12, 3H12, and 3H12/ cells were routinely maintained in DMEM-F12
(GIBCO™) culture medium supplemented with 5% fetal calf serum, 200mM L-glutamine,
and ABAM. Cells were transferred to steroid-free medium JAC-0.5 containing 1:1
F12/M199, ABAM, 0.5% charcoal-stripped fetal bovine serum (Hyclone), 0.25% ITS+™
(insulin-transferrin-selenium plus lipoic acid, Becton Dickinson), 0.1mM
phosphorylethanolamine (Sigma) and 2mM glutamine (GIBCO™) prior to hormonal
stimulation. The stromal medium and JAC-0.5 treatment media were phenol red-free. All
cultures described in this report were maintained at 37oC in a humidified atmosphere of 5%
CO2.
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Immunodetection of Hormone Receptors. Cultures were washed in cold saline buffer
and scraped in 52µl/cm2 of modified RIPA buffer [50mM Tris-HCl, pH 7.4; 150mM NaCl;
1mM EDTA; 1% NP-40 detergent; 0.25% sodium deoxycholate; 1mM
phenylmethanesulphonylfluoride (PMSF); 1µg/ml each of aprotinin, leupeptin, pepstatin;
1mM sodium orthovanadate and 1mM sodium fluoride]. The resuspended cells were
transferred to a 1.5ml microcentrifuge tube and incubated on ice for 30minutes, then
centrifuged at 13,000xg for 30 minutes. The supernatants were assayed for total protein
concentration using a bicinchonicic acid assay (Pierce Chemical Co.). Proteins in the cell-
free extracts were separated by SDS-PAGE in 10% polyacrylamide and electrotransferred
onto a nitrocellulose membrane. TBS/0.1% Tween-20 buffer [20mM Tris-HCl, pH 7.6;
73mM NaCl; and 0.1% Tween-20] was used for all steps of the immunodetection and each
step was preceded by three 5-minute washes at room temperature. Blocking was conducted in
5% nonfat dry milk for 1 hour at room temperature. The blot was incubated overnight at 4ºC
with primary antibody diluted in 5% BSA- TBS/0.1% Tween-20, then exposed to secondary
antibody linked to horseradish peroxidase (Amersham) [1:2000 in 5% non fat dry milk in
TBS/0.1% Tween-20] for 1 hour at room temperature. For protein detection, the blot was
incubated in a luminol substrate (Pierce) for 5 minutes, covered in plastic wrap and exposed
to X-ray film. Primary antibodies used were: anti-estrogen receptor  mouse monoclonal
[1:1000 dilution; Cell Signaling Technologies, Inc.], anti-estrogen receptor  rabbit
polyclonal [1:1000 dilution; Upstate].
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Retrovirus production and cell line construction. ESR1, the human gene encoding the
estrogen receptor  protein was obtained from the laboratory of Dr. Donald P. McDonnell at
Duke University. This gene cDNA was encoded within the pV16 expression vector
(Clontech). The ESR1 gene was excised from pV16 by digesting with the EcoR1 restriction
enzyme (New England Biolabs). The resulting digest was electrophoresed on agarose to
separate the digested ESR1 gene fragment from the empty pV16 vector. The desired
fragment was purified with Gene Elute minus ethidium bromide (Sigma) and subsequently
ligated into the multiple cloning site of EcoR1 digested pQXCIN, a retroviral backbone with
a neomycin resistance marker (BD Biosciences). Competent bacteria were transformed with
the ligated pQXCIN-ER constructs and grown on Luria Miller Agar plus ampicilian culture
plates. Clones were picked and grown in Luria Broth (LB) media plus ampicilian. DNAs
were then isolated from the bacteria and digested with the Eco R1 restriction enzyme to
ensure that the clone contained the cDNA insert. Following the identification of positive
clones digests with the BGL II restriction enzyme (New England Biolabs) were conducted to
ensure proper orientation of the gene cDNA sequence within the pQXCIN backbone.
Following identification of properly oriented constructs, large scale preparations were
conducted followed by DNA sequencing to ensure fidelity of the cDNA sequence.
The full length ESR2, the human gene encoding the estrogen receptor  protein was
obtained from the laboratory of Dr. Sohaib Khan in the Department of Cell Biology at the
University of Cincinnati. The ESR2 DNA was encoded on the pcDNATM3.1 expression
vector. Sequencing was carried out to ensure that this DNA was the full-length ER cDNA
and to ensure fidelity of the construct. The ESR2 sequence was amplified from the vector
using primers, Forward- 5’-CCC GGA TCC ATG GAT ATA AAA AAC TCA C-3’ and
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Reverse- 5’-CCC GGA TCC TCA CTG AGA CTG AGA CTG TGG GTT C-3’, which
placed Bam H1 restriction sites and Kozak fragments at the 5’ and 3’ ends of ESR2. PCR
reactions were run with Proof-StartTM Taq Polymerase (Qiagen) at 95oC-15 minutes
(activation of the polymerase), and cycled at 94oC-30 seconds, 58oC-30 seconds, and 72oC-
1.5 minutes for 32 cycles. PCR products were electrophoresed on agarose and excised. The
ESR2 gene cDNA was purified with Gene Elute minus ethidium bromide (Sigma) and
subsequently digested with the Bam H1 restriction enzyme (New England Biolabs). The
desired fragment was ligated into the multiple cloning site of Bam H1 digested pQXCIP, a
retroviral backbone with a puromycin resistance marker (BD Biosciences). Competent
bacteria were transformed with the ER-pQXCIP construct and grown on Luria Miller Agar
(Gibco) culture plates. Clones were picked and grown in Luria Broth (LB) media plus
ampicilian. DNAs were prepared and digests with Bam H1 were carried out to identify
clones containing the cDNA insert. Following identification of positive clones, digests with
BGL II and Eco RV restriction enzymes (New England Biolabs) were conducted to ensure
proper orientation of the gene sequence within pQXCIP. Following identification of properly
oriented constructs, DNA sequencing was carried out to ensure fidelity of the sequence.
As described above, the ESR1 and ESR2 DNA sequences were subcloned into the
retroviral expression vectors pQCXIN and pQCXIP (BD Biosciences), respectively.
Vesicular Stomatitis Virus-G pseudotyped, replication-incompetent retroviruses were
produced by transient three-plasmid transfection into HEK-293T host cells (Soneoka et al.
1995). Retroviruses were pelleted and resuspended in 1ml 1X Hanks Buffered Saline
Solution (HBSS) plus Ca+, Mg+. Recipient cells, Ishikawa-3H12, were plated at a density of
fifty-thousand cells in a 100mm plate were infected with the retroviruses preparations (1X-
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450uL or .1X-45ul) in the presence of 8 µg/ml hexadimethrine bromide (Sigma) for 6 hours.
This treatment was repeated the next day. Starting on day 3, transduced cells and a mock-
infected control were treated with Neomycin (400µg/ml), pQXCIN-ER, or Puromycin
(400ng/ml), pQXCIP-ER, for 10 days. During this interval, the control uninfected cells
died. Survivor cells in the infected culture were amplified and used for experiments described
herein. Cells expressing ER were named 3H12 and were used as a population, while those
expressing ER were named 3H12 and were cloned revealing several clones expressing
various levels of ER. All studies conducted within this dissertation were completed using
3H12 clone 13. A third cell line expressing both ER and ER, 3H12, was constructed
using the 3H12 clone 13 cells and re-infecting them with the pQXCIN-ER retroviral
preparations. The cells were then subjected to selection with neomycin for 10 days. Survivor
cells were amplified and used as a population.
Cellular proliferation. To assess proliferation, cells were seeded at a density of 5x105
cells in 60mm tissue culture dishes (Corning). Test compounds were dissolved in ethanol and
were diluted in JAC-0.5 medium (final concentration of ethanol, 0.1%), which was applied
on days 0 and 2. Three representative dishes were counted as base line for the beginning of
the assay. Cells were detached from the dishes using a 1:1 mix of trypsin:EDTA and Versene
(GIBCO™) at 37oC for five minutes. Stromal medium was added to stop the reaction.
Trypsonized cells were thoroughly mixed to obtain single cell suspensions, and enumerated
with a Coulter Counter (Beckman Coulter, Inc., Fullerton, CA).
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BrdU incorporation assays. To assess cell cycle profiles, cells were seeded at a
density of 5x105 cells in 60mm tissue culture dishes (Corning, Corning, NY) in triplicate.
17-estadiol was dissolved in ethanol and was diluted in JAC 0.5 medium (final
concentration of ethanol, 0.1%), which was applied on days 0 and 2. BrdU stock solution was
added to a final concentration of 10µM to each dish on day 4 and incubated with BrdU for 1
hour at 37oC. Cells were detached from the dishes using a 1:1 mix of trypsin:EDTA and
Versene (GIBCO™) at 37oC for five minutes. JAC-0.5 medium was added to stop the
reaction and trypsonized cells were pelleted at 1200 revolutions per minute (RPM) for 5
minutes at 4oC. Supernatant was removed and the cell pellet was washed with 1xPBS and
cells were pelleted at 1200 RPM for 5 minutes at 4oC. Supernatant was removed and 1.5ml of
cold 1xPBS was added while vortexing the cells followed by 3ml of cold 100% ethanol.
Cells were stored in the dark at 4oC overnight.
Nuclei were placed into suspension by vortexing and were subsequently pelleted at
1000 RPM for 5 minutes at 4oC. Supernatant was removed and 3ml of 0.8% pepsin in 0.1 N
hydrochloric acid (HCl) was added while vortexing. Nuclei were incubated at 37oC for 20
minutes. Nuclei were pelleted at 1000 RPM for 5 minutes at 4oC and supernatant was
removed. 1.5ml of 2 N HCl was added to nuclei while being vortexed followed by a 20
minute incubation at 37oC. Nuclei were vortexed and 3ml of 0.1 M sodium borate was added.
Nuclei were pelleted at 1000 RPM for 5 minutes at 4oC. Supernatant was removed and the
nuclei were vortexed then 100µl of BrdU diluted 1:5 in IFA [10mM HEPES, 150mM NaCl,
4% fetal bovine serum, and 0.1% NaN3] plus 0.5% Tween-20 was added. Nuclei were
pelleted and RNase A (Roche Biomedical) was added to a final concentration of 5µg/ml.
Propidium iodide was added to bring the concentration to 50µg/ml. Nuclei were then
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incubated overnight at 4oC. Supernatant was removed from the nuclei following the
overnight incubation at 4oC. Nuclei were vortexed and IFA plus 0.5% Tween-20 was added.
Nuclei were transferred to appropriate tubes for the FACS machine and were analyzed the
same day.
Results
Proliferative response to 17-estradiol between the Ishikawa and Ishikawa-3H12 cell
lines. Endometrial cancer has been linked to increased proliferation of the endometrial
epithelial cells in response to unopposed estrogens (Kurman et al. 1985). To study this
phenomenon in an in vitro model system we characterized the effects of physiologic
concentrations of 17-estradiol on proliferation of both Ishikawa and Ishikawa-3H12 cells.
This treatment revealed that Ishikawa, and not IK 3H12, cells respond to 17-estradiol
treatment in a proliferative manner (Figure 4.1). Furthermore, the increase in proliferation, in
response to estrogen, of Ishikawa cells can be inhibited using the total ER/ inhibitor, ICI
182780 (Figure 4.2). This finding suggests that the estrogen receptors are indeed responsible
for the increased proliferation of endometrial epithelial cells to physiologic concentrations of
17-estradiol.
Response of the Ishikawa cells to receptor-type specific ER agonists. The recent
commercial release of specific agonists of the ER and ER, PPT and DPN, respectively, has
provided valuable new agents for the elucidation of the functions of each ER subtype. In this
study, we utilized these agonists in the Ishikawa cell line to understand the contributions of
each receptor subtype on proliferation. Treatment with PPT or DPN
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Figure 4.1. 17-estradiol Treatment Increases Proliferation of Ishikawa and not
Ishikawa-3H12 cells. Cells were treated with 10-8M 17-estradiol or vehicle (ethanol)
and assayed on indicated days. Cells were harvested and enumerated by Coulter
Counter®. * indicates significant change (p<0.05) as compared to vehicle treated cells.
** indicates significant change (p<0.05) as compared to Ishikawa cells.
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Figure 4.2. Ishikawa Proliferation is increased by ER, but not by ER. Cells were
treated with 10-8M 17-estradiol, 10-8M PPT (ER agonist), or 10-8M DPN (ER
agonist) +/- 10-7M ICI 182780 (ER Inhibitor) and assayed on indicated days. Cells were
harvested and enumerated by Coulter Counter®. * indicates significant change (p<0.05)
as compared to vehicle treated cells.
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revealed that activation of ER, and not ER, could induce proliferation of the Ishikawa cells
(Figure 4.2). Again, the effects of the ER agonist, PPT, could be inhibited using the
powerful antiestrogen ICI 182780, which blocks estrogen mediated effects on both ER and
ER. This shows that the response to the agonist is in fact mediated through the ERs (Figure
4.2). Taken together, this data suggests that ER is the primary receptor involved in growth
stimulation in response to estrogens. However, we cannot fully appreciate the individual
contributions of each receptor subtype in this cell line, as the receptors are both expressed.
To distinguish the effects of the two receptors, it would be necessary to study cells
expressing only one or the other receptor.
Construction of Ishikawa-3H12 expressing ER and/or ER. Conclusions drawn from
the use of the agonists remain subject to some question because these compounds are not
completely specific. The development of cells that expresses either receptor alone is a logical
means to verify and extend these results. We chose to use an isogenic cell line, Ishikawa-
3H12, to pursue further studies. The Ishikawa-3H12 cells were obtained from Dr. Leen Blok
and have been reported to lack functional expression of either ER subtype (Hanekamp, et al.
2003). We found that the Ishikawa 3H12 cell line lacks both mRNA and protein expression
of both ER subtypes, which explains why they are incapable of responding to 17-estradiol.
To consider the individual roles of the ERs in carcinogenesis of the endometrium we must
first investigate the individual roles of each receptor in proliferation. Therefore, the Ishikawa
3H12 cells were stably transfected using reterovirus specific for each ER subtype, either
alone or together. As a result of these studies we obtained three new cell strains, named
3H12, 3H12, and 3H12. To access the biology of
119
Figure 4.3. Protein Expression of ER Constructed Cell Lines. 30µg of total cell protein
from Ishikawa, 3H12, 3H12, 3H12, and 3H12 populations were loaded and run on a
SDS-page gel. Antibodies against ER, ER, and GAPDH were used to determine protein
expression within each cell line. (MCF-7 cell lysates were used as a positive control and
are not shown.)
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these cell strains, the presence of the receptor protein was confirmed by Western Immunoblot
analysis (Figure 4.3).
Response to 17-estradiol by Ishikawa-3H12 cells expressing ER’s. Construction of
the ER expressing Ishikawa-3H12 cell lines (3H12 and 3H12) has facilitated
understanding of the functions of these receptors in endometrial adenocarcinoma cells. Cell
proliferation assays revealed in 3H12, cells expressing ER, a 103% increase in growth
when compared against the parental 3H12 cells after 4 days of culture. The expression of
ER in the 3H12 cells makes their constitutive proliferation rate comparable to that of the
normal Ishikawa cells (Figure 4.4). The 3H12 cells that express ER had a 45% decrease in
proliferation. This is significant as compared with the parental cell line, suggesting that ER
activity reduces the proliferation of human endometrial adenocarcinoma cells (Figure 4.5).
Treatment of both ER constructed cell lines with 10-8M 17-estradiol revealed
significant increases in growth over vehicle-treated cells. In fact, treatment of the 3H12
cells lead to a 40% increase in proliferation, which essentially restored the ability of the
3H12 cell lines to proliferate like Ishikawa cells (Figure 4.4). This finding indicates that ER
may be the primary receptor subtype responsible for the proliferative response to estrogens in
Ishikawa endometrial epithelial cells. On the other hand, treatment of the 3H12 cell line
with 17-estradiol produced a 39% increase in proliferation (Figure 4.5). Although treatment
of the 3H12 cells with physiologic concentrations of 17-estradiol produce a significant
increase in proliferation, these cells fail to reach the levels of proliferation seen in the
parental strain, 3H12. Taken together, these observations suggest a stimulatory role for ER
and an inhibitory role for ER.
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Figure 4.4. Comparison of 3H12 and 3H12 Cell Proliferation Rates. Cells were
treated with 10-8M 17-estradiol or vehicle (ethanol) and assayed on indicated days. Cells
were harvested and enumerated by Coulter Counter®. The result indicate that the
reconstitution of ER in the 3H12 cells leads to increased cellular proliferation and the
ability to respond to estrogens. * indicates significant change (p<0.05) as compared to
vehicle treated cells. ** indicates significant change (p<0.05) as compared to Ishikawa-
3H12 cells.
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Figure 4.5. Comparison of 3H12 and 3H12 Cell Proliferation Rates. Cells were
treated with 10-8M 17-estradiol or vehicle (ethanol) and assayed on indicated days.
Cells were harvested and enumerated by Coulter Counter®. The results indicate that the
reconstitution of ER in the 3H12 cells leads to a significant decrease in cellular
proliferation. However, the 3H12 cells display a modest increase in proliferation in
response to estrogens. ** indicates significant change (p<0.05) as compared to
Ishikawa-3H12 cells.
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Cell cycle profiles of Ishikawa-3H12 ER expressing cells. The results of the
proliferation assays utilizing the Ishikawa-3H12 cells expressing ER or ER provided novel
information regarding the roles of these receptors in human Ishikawa endometrial epithelial
cells. The fact that introduction of ER, in the absence of 17-estradiol, restores the ability of
the Ishikawa-3H12 cells to proliferation at rates comparable to that of conventional Ishikawa
cells is remarkable. Furthermore, the introduction of ER significantly, in the absence of
17-estradiol, reduced the ability of the Ishikawa-3H12 cells to proliferation. BrdU
incorporation followed by flow cytometry assays were undertaken to evaluate the cell cycle
profiles of these cells lines, in a search for possible mechanisms of the increase (3H12 cells)
or decrease (3H12 cells) in cellular proliferation. The flow cytometry data showed no
significant differences between the profiles of Ishikawa-3H12 and 3H12 cells (Figure 4.6 b
and c). Unfortunately, this finding does not help us understand the mechanisms by which
ER expression in the Ishikawa-3H12 cells leads to increased proliferation. More puzzling is
the fact that conventional Ishikawa cells have a greater population of cells in G1 and fewer
cells in the synthesis (S)-phase and G2 phases of the cell cycle than Ishikawa-3H12 cells
(Figure 4.6 a and b). However, a reasonable explanation for the conventional Ishikawa and
the 3H12 cells may be that they simply progress through the cell cycle at a faster rate than
the Ishikawa-3H12 cells.
Despite the data collected from conventional Ishikawa and 3H12 cells, flow
cytometry data showed that Ishikawa-3H12 cells expressing ER (3H12) had an S-phase
population of 22% (Figure 4.6 b), while the parental strain (3H12) had an S-phase population
of 34% (Figure 4.6 d). This observation is consistent with our findings that ER reduces
proliferation of the Ishikawa cells. This finding is also consistent with the observation that
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ER negatively regulates cyclin D1, a key component needed for the G1/S transition of the
cell cycle, leading to a reduction in the S-phase population of cells thereby leading to a
reduction in proliferation in T47D and MCF7 breast adenocarcinoma cells (Hartman, et al.
2006; Paruthiyil et al. 2004; Strom et al. 2004).
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Figure 4.6. Comparison of Cell Cycle Profiles of Conventional Ishikawa,
Ishikawa-3H12, ER and ER expressing cells. Ishikawa (a), Ishikawa-3H12 (b),
3H12 (c), and 3H12 (d) cells following BrdU incorporation. 3H12 cells have
fewer cells in the Synthesis (S)-phase of the cell cycle (22%) as compared to the
partenal Ishikawa-3H12 cell line (34%). This indicates that introduction of ER may
inhibit the G1 phase of the cycle.
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Discussion
Up to the present, most studies on the function of the estrogen receptors have utilized
transient transfections of the ERs or techniques to reduce the expression of the ERs,
including the introduction of small interfering RNA (siRNA) or oligodeoxyribonucleotides
(ODN) into endometrial target cells (Ali, et al. 2000; Taylor, et al. 2002; Zhang, et al. 2006).
Although these techniques have proved to be useful by providing a foundation for further
studies, data collected from them cannot provide a definitive answer with regard to specific
receptor function. In the current study, we utilized a system in which the estrogen receptors
were stably transfected into a line of cells manifesting an ER null-background. The level of
expression of the ERs that were detected in the cell lines we constructed are not increased
excessively, rather they are comparable to those in the Ishikawa cell line (Figure 4.3). The
construction of the Ishikawa-3H12 derived cell lines expressing ERs (3H12 and 3H12) has
provided an alternative approach to studying the individual ER’s that should aid our
understanding of the functions of these receptors in endometrial adenocarcinoma cells.
Ishikawa endometrial adenocarcinoma cells, an established endometrial epithelial
cancer cell line, have been used extensively to study the effects of estrogens and selective
estrogen receptor modulators (SERMS) in the human endometrium. Recently, it was
recognized that the Ishikawa cell line consisted of a heterogenous population containing cells
with varying ER expression profiles (Nishida, et al. 1996). Subsequently, this cell line was
cloned revealing several new cell lines with specific ER phenotypes (Nishida 2002; Nishida
et al. 1996). In the current study, we utilized the original Ishikawa cells and the Ishikawa-
3H12 clone, which lacks expression of either ER subtype (Nishida et al. 1996). Initial studies
revealed a significant increase in the proliferation of the conventional Ishikawa cells and not
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in the Ishikawa-3H12 clone, when they were treated with physiologic concentrations of 17-
estradiol. This finding, along with the results of the Western immunoblot analysis showing
the absence of ER or ER, validated that the 3H12 clone lacked functional ER expression,
thereby rendering these cells incapable of responding to estrogens or SERMS via a receptor
mediated mechanism.
In an effort to understand the contributions of the two different estrogen receptors, we
also used two commercially available specific agonists of the ER and ER, Propylpryazole-
triol (PPT) and Diarylpropionitrile (DPN), respectively. Treatment of the 3H12 clone with
the agonists revealed no change in proliferation as compared to vehicle treated samples,
further solidifying the observation of a lack of ER expression (Figure 4.1). However,
treatment of the conventional Ishikawa cells with either agonist revealed increases in
proliferation, which could be prevented by treatment with the antiestrogen ICI 182780. These
findings indicate that the ER agonist can induce estrogen receptor-mediated proliferation of
endometrial adenocarcinoma cells. Furthermore, we know from the studies using ICI 182780
that the effects of both agonists are in fact mediated through the ERs.
To confirm the findings obtained by using the highly specific agonists in the Ishikawa
cell system, we created cell lines that express the ER subtypes individually. To complete this
task we used the Ishikawa-3H12 clone, an isogenic cell line which lacks functional
expression of either ER subtype (Hanekamp et al. 2003; Nishida et al. 1996). When cells
expressing the receptors were tested, we noticed a restoration of proliferation in the 3H12
cells. In fact, these cells proliferated at approximately the same rate as the normal Ishikawa
cell line, indicating that ER is probably the primary receptor involved in stimulation of
Ishikawa cell proliferation. On the other hand, the 3H12 cells showed a reduced capacity to
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proliferate when compared against the parental 3H12 cell line, indicating that ER may have
an opposing function in the context of this model system. However, when treated with 17-
estradiol, the 3H12 cells showed a modest but significant increase in proliferation,
indicating that this receptor can also positively influence proliferation in response to ligand.
In summary, the data from this study suggests that ER is the major receptor subtype
involved in the constitutive and estrogen-induced proliferation of Ishikawa cells. Treatment
of the Ishikawa cells with PPT, the highly specific ER agonist, revealed a 121% increase in
proliferation after 4 days of treatment (Figure 4.2). Additionally, its expression alone
reconstitutes the exaggerated estrogen response seen in the conventional Ishikawa cell line
(Figure 4.4). On the other hand, ER appears to reduce proliferation by impeding the G1/S
transition of the cell cycle, possible due to decreased levels of cyclin D1 (Figure 4.6).
However, without further studies we cannot rule out the possible involvement of other cell
cycle proteins as Strom et al. (2004) suggested that many other components of the cell cycle
associated with proliferation, e.g. cyclin E and Cdc25A, were decreased with ER expression
in T47D breast cancer cells (Strom et al. 2004). Activation of this cell line with 17-estradiol
suggests that ER can induce proliferation in this model system. However, the estrogen-
induced increase in proliferation observed in the 3H12 cells never reach the proliferation
levels of the parental 3H12 cell line, indicating that the increase is at best modest and well
controlled. Our observations are consistent with findings in the breast, ovary, prostate, and
colon regarding ER’s inhibitory effects in the epithelium of these tissues with respect to
ligand-induced proliferation (Bardin et al. 2004; Brandenberger et al. 1998; Campbell-
Thompson et al. 2001; Fixemer et al. 2003; Foley et al. 2000; Horvath et al. 2001; Latil et al.
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2001; Park et al. 2003; Pujol et al. 1998; Roger et al. 2001; Rutherford et al. 2000; Zhao et al.
2003).
Chapter V: Experimental Conclusions
Alteration of the ER/ER Ratio in the Human Endometrium
Recent in vitro studies focusing on the roles of the estrogen receptors  and  in the
epithelium of breast suggests divergent roles for the receptor subtypes. An overwhelming
majority of in vitro data suggests that ER is stimulatory and ER is inhibitory to cell
proliferation and differentiation in breast epithelium. Further studies in several human tissues
have shown alterations in the ratio of ER to ER in diseased specimens. Herein, we provide
evidence that is consistent with findings of an altered ER ratio in human endometrial cells as
has been seen in other human tissues, including breast, ovary, prostate, and colon. Utilizing
TMA technology and immunohistochemistry (IHC), we were able to observe an alteration in
the normal nuclear ER/ER ratio in the stromal and epithelial compartments of the human
endometrium. This alteration was observed in hyperplastic human endometrium, which is a
critical phase in estrogen-dependent endometrial neoplasia, as twenty-five percent of the
most severe cases progress into endometrial adenocarcinomas. Morover, the stromal and
epithelial compartments of malignant samples revealed alterations in the “normal” ER/ER
ratio. Alterations of the ER/ER ratio in the studies described here involve a relative
increase in ER, suggesting that this receptor subtype is primarily responsible for the
increased proliferation seen in the hyperplastic and malignant tissues. At the same time the
relative decrease in ER may remove an impediment to proliferation or a limiting control of
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this process. Furthermore, this observation strongly suggests that maintaining a normal
receptor ratio is essential to a normal response to estrogens within this tissue
microenvironment.
Immunohistochemical studies that evaluated cytoplasmic staining of the receptors
revealed patterns consistent with the hypothesis that a relatively high level of ER is found in
normal endometrium and may serve to impede cell proliferation in the human endometrium.
First, immunostaining of ER in the cytoplasm of stromal cells showed that approximately
5% of normal cells were positive, while there was no cytoplasmic immunostaining detected
in hyperplastic or malignant samples. On the other hand, 0% of normal stromal cells stained
positively for cytoplasmic ER, while 6% of the cells in the hyperplastic and 10% of the cells
in the malignant samples were positive (Figure 2.4).
Positive results for ER immunostaining of the cytoplasm of epithelial cells were
found in 13% of normal cells; 61% of hyperplastic samples; and 22% malignant cells. On the
other hand, 55% of normal epithelial cells demonstrated cytoplasmic ER staining, while
hyperplastic samples revealed a slight reduction to 43%. Furthermore, a significant increase
in cytoplasmic ER staining in the malignant epithelial cells was observed, where 91% of
epithelial cells were positive (Figure 2.5). The significance of changes in receptor levels in
stromal cells from malignant samples must be considered with regard to the notable
reduction in stromal cells in the immediate environment of the epithelial tumor cells.
The results obtained in pursuit of this aim are consistent with the hypothesis that
normal conditions are defined by a balance between ER and ER. ER is deduced to be an
inhibitor of cell proliferation in the human endometrium. This deduction is based on the
observation that the expression levels of ER decrease from their homeostatic level during
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the progression of endometrial cancer and the increasing cell proliferation associated with
this change. We have found significant alterations in the normal homeostatic expression of
the receptor subtypes in hyperplastic endometrial tissue samples. We interpret these
alterations as leading to an abnormal environment in which the relative level of ER is
increased over that of its counterpart ER. These observations appear to be consistent with
the overall hypothesis regarding the independent roles of the receptors, in that ER is a
stimulator of growth while ER serves as an inhibitor of proliferation.
The Roles of the Estrogen Receptors  and  in Gene Regulation
In Chapter III, we present results that support the hypothesis that 17-estradiol acts
through ER to exert an inductive effect on gene regulation in the human Ishikawa cells.
This interpretation was based on observations using PPT, a specific agonist of ER. It was
also deduced from studies that used Ishikawa cells that express only the ER (3H12 cell
line). These studies showed that estrogenic induction on ER increases both the quantity of
mRNA transcribed from the placental alkaline phosphatase (ALPP) gene as well as ALPP
activity in the cells. We were neither able to confirm nor deny the classic estrogen signaling
pathway in the involvement of the regulation of ALPP. Our data, however, does provide
evidence that upregulation of ALPP, our model estrogen-inducible gene, is mediated at least
in part, through the activation of the MAPK and (PI)3-kinase pathways in response to
treatment with 17-estradiol. This finding provides support for the existence of membrane
and/or cytoplasmic actions of the estrogen receptors. We were unable to conclude that ER is
inhibitory with regard to the regulation of the ALPP gene induction using the specific agonist
DPN or when using the 3H12 cell line, which only expresses the ER gene. However, we
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can conclude that if ER functions in the cytoplasm it does not appear to be inhibitory with
regard to the induction of ALPP gene expression.
The Roles of the Estrogen Receptors  and  in Cellular Proliferation
In Chapter IV, we present data consistent with the hypothesis that ER is the key ER
responsible for proliferation, while ER is inhibitory in Ishikawa epithelial cells. In an effort
to understand the individual contributions of the receptors, we utilized two commercially
available highly specific agonists of the ER and ER, Propylpryazole-triol (PPT) and
Diarylpropionitrile (DPN), respectively. Treatment of Ishikawa cells with PPT, but not DPN,
revealed an increase in proliferation, which could be prevented with the ER inhibitor ICI
182780. These findings show that ER is the primary receptor involved in the induction of
estrogen receptor mediated proliferation of these endometrial adenocarcinoma cells.
To confirm the findings in studies that use the specific agonists for ER and ER in
Ishikawa cells, cell lines that express either ER or ER individually (3H12 and 3H12)
were created and validated. After constructing cells expressing these receptors, restoration of
proliferation in the cells expressing the ER gene (3H12) was observed. In fact, these cells
proliferate at approximately the same rate as the normal Ishikawa cells, and much more
rapidly than the 3H12 cells from which they were derived. Again this indicates that ER is
the primary receptor involved in Ishikawa cell proliferation. On the other hand, the 3H12
cells showed a reduced capacity to proliferate when compared to the parental 3H12 cell line,
indicating that ER may have an opposing action on the proliferation of Ishikawa cells.
When treated with 17-estradiol, the 3H12 cells showed a modest but significant increase in
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proliferation, indicating that this receptor can produce some positive influence on cell
proliferation in response to the ligand.
Taken together, our results show that ER is the major receptor subtype involved in
the constitutive and estrogen-induced proliferation of Ishikawa cells. Treatment of the
Ishikawa cells with PPT, the specific ER agonist, produced a 121% increase in proliferation
after 4 days of treatment. Additionally, the expression of ER alone reconstitutes the
exaggerated estrogen response seen in the Ishikawa cell line. On the other hand, ER appears
to reduce the proliferation. Additionally, when cells expressing only ER (3H12) were
treated with BrdU and compared against the parental cells, we observed a significant
reduction in the S phase population. Since ER is known to reduce the mRNA levels of
cyclin D1, a key mediator of the G1/S transition, it may act to impede cell cycle progression,
possibly in the G1 phase.
How We Addressed the Proposed Hypothesis
Our original hypothesis was that the Estrogen Receptor  acts as a modulator of the
Estrogen Receptor  in the human endometrium. To address this hypothesis we pursued three
Specific Aims as part of the original research proposal. These Aims and supporting evidence
are as follows:
Specific Aim I. Determine the Relative Levels and Expression Patterns of ER and  in
Normal, Hyperplastic, and Malignant Endometria.
Herein we provide evidence of an alteration in the ratio of ER to that of ER in
human endometrial tissue as it transitions toward malignancy. There are two broad
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explanations for the IHC findings contained within this dissertation. The first explanation is
that alterations in the ER expression levels leading to alterations in the stromal and epithelial
compartments are haphazard events that are meaningless with regard to carcinogenesis of the
human endometrium. However, based on our current understanding of the biology of the
ERs, estrogen being the classic etiologic risk factor type-1 endometrial lesions, and our
statically significant results, we do not believe that these changes are simply haphazard
events. The second explanation is that changes in the ER expression levels are in fact
meaningful and reveal a possible mechanism that permits the endometrium to become
hypersensitive to estrogens. When considering the second explanation, in concert with our
current understanding of the functions of the ER subtypes in other tissue types, the general
roles for the receptors in progression of endometrial cancer become apparent.
Using Dako® antibodies against the estrogen receptor subtypes we were able to observe
alterations in the frequency and intensity of ER staining in both hyperplastic and malignant
endometrial tissue samples. First, we were able to show an alteration from the normal ratio in
stromal cells. In stromal cells from hyperplastic tissues, this change was observed as a
decrease in ER intensity, while ER remained the same as those in normal tissue samples
(Chapter II). We observed a significant decrease in ER immunostaining and a significant
increase in ER immunostaining in stromal cells from malignant tissues. We believe that this
may be an adaptive response by the stromal cells to constrain the proliferation of the
epithelium in response to estrogens. However, the size of the stromal compartment in
malignant endometrial tissue is diminished in size and therefore cannot produce the
necessary paracrine factors to reduce the excessive proliferation of the epithelial
compartment.
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Additionally, we observed an alteration of the ratio in the epithelial compartment. Unlike
the stroma, alterations in the epithelium was manifested by an increase in the intensity of
ER staining in the nuclei of epithelial cells from hyperplastic tissues and these elevated
levels persisted in the epithelium of malignant samples. ER expression was the same in the
normal and hyperplastic samples but increased significantly in malignant samples. One might
speculate that the increase in expression of ER may be a result of the epithelial cells
responding to modulate the high rate of proliferation in response to estrogens. However, we
think that alterations/mutations in various signaling pathways, including (PI)3-kinase and
MAPK, as a result of loss of the PTEN tumor suppressor gene, can help overcome any
beneficial inhibitory effects that ER may have. Furthermore, we have shown in the studies
in Aim 3 (Chapter IV) that ER activity reduces cellular proliferation. However, cells
expressing this receptor can undergo a modest but significant increase in proliferation in
response to estrogen. Therefore, it is possible that the endometrial adenocarcinoma cells may
harness this response to further increase proliferation of epithelial cells in response to
estrogens.
The work presented in this Specific Aim provides novel insight into mechanisms that
may permit the human endometrium to become hypersensitive to estrogens. First, evidence
utilizing immunohistochemistry (IHC) suggests an alteration in the ratio of ER to ER in
hyperplastic endometrial samples, which is consistent with findings in the breast, prostate,
colon, and ovaries (Bardin et al. 2004; Brandenberger et al. 1998; Campbell-Thompson et al.
2001; Fixemer et al. 2003; Foley et al. 2000; Horvath et al. 2001; Latil et al. 2001; Park et al.
2003; Pujol et al. 1998; Roger et al. 2001; Rutherford et al. 2000; Zhao et al. 2003). Clinical
findings and the current literature suggests that a small portion of endometrial hyperplasias
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transition to malignancy. What is not known is whether the alteration in the ER profile is a
determining factor in the transition of hyperplasia to cancer.
Specific Aim II. Characterize the Roles of the Estrogen Receptors  and  on Estrogen-
Induced Gene Regulation in Human Endometrial Epithelial Cells.
Using agonists of the estrogen receptors and cell lines that express either receptor
subtype alone, we have been able to elucidate the roles of the estrogen receptors on the
regulation of the placental alkaline phosphatase gene (ALPP). We have shown that the ER
is the primary receptor involved in the upregulation of ALPP by utilizing highly specific
agonists of the ER’s. In the case of the ER agonist, PPT, we noticed an increase in ALPP
activity at concentrations as low as 10-10M. Further studies using 3H12 cells revealed that
these cells increase the expression of ALPP in response to physiologic concentrations of 17-
estradiol. Studies evaluating the regulatory role of ER showed that signaling through this
receptor had no impact on ALPP. These studies included use of the ER agonist, DPN, and
3H12 cells, which express the  subtype only.
Additional studies were aimed at understanding how the ALPP gene was regulated at
the molecular level. Two putative estrogen response elements (EREs) were identified within
the 5’ flanking region of ALPP. Chromatin Immunoprecipitation (ChIP) assays were unable
to detect either ERE in DNA fragments precipitated with antibodies against the receptors.
Although we were unable to precipitate the receptors bound to either ERE we are not able to
exclude the possibility that these interactions are present, as levels of binding may be below
the sensitivity of this assay. Further studies explored the non-classic activation of the ER’s
and the stimulation of the MAPK and (PI)3-kinase pathways in response to treatment with
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17-estradiol. We were able to inhibit the upregulation of ALPP by 17-estradiol using
inhibitors of either MAPK or (PI)3-kinase, U0126 or LY294002, respectively. These results
suggest that both pathways are activated by ER present in the membrane or cytoplasm of
these cells. Furthermore, the data presented in Chapter III provides supporting evidence that
endometrial epithelial cells contain membrane and/or cytoplasmic ERs which can activate
cell survival cytoplasmic pathways such as (PI)3-kinase and MAPK to elicit effects on target
genes.
An additional explanation for our observations may be that activation of the (PI)3-and
MAP Kinase pathways by 17-estradiol activates the ligand-independent (AF-1) region of
nuclear ER through crosstalk thereby positively influencing transcription of the ALPP gene.
However, the analysis of the 5’ flanking region of the gene with the Dragon ERE Finder
revealed two putative EREs located approximately 2000 basepair away from the TATA start
site on the reverse complement strand. Moreover, this software predicted that both putative
EREs would have an extremely low probability of being actual response elements. Therefore,
regulation of the ALPP gene through nuclear ER, via the classic or non-classic pathway, may
not be an accurate reflection of the normal biology of this gene. Furthermore, we were unable
to demonstrate, by ChIP, that either of the ERs bound to the putative response elements. This
suggests that crosstalk from the cytoplasmic signaling pathways to nuclear ER, which in turn
regulates genes by binding to EREs, is unlikely to be a plausible explanation for these
observations at this time.
An additional explanation comes from the idea that activation of the cytoplasmic
pathway, MAPK, by growth factors has been implicated in stimulating the activity of p160
coactivator family members (Lopez, et al. 2001). As discussed in the Introduction to this
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dissertation (Chapter I), the p160 proteins are critically important in ER-mediated
transcription. Therefore, it may be reasonable to assume that inhibition of the (PI)3-Kinase
and MAPK cytoplasmic pathways serves to reduce the activity of p160 coactivators, which
would lead to a decrease in ER mediated transcription. However, this explanation may not
fully explain the observations contained within Chapter III, as the current literature does not
suggest that the ERs need active coactivators to induce transcription.
Introduction of ER into 3H12 cells revealed an increase in ALPP activity over that
of parental Ishikawa-3H12 cells. However, when compared to conventional Ishikawa cells,
upregulation of ALPP by the 3H12 cells appears to be “weak”, which may suggest that ER
is insufficient in the upregulation of this gene or that other required factors are missing. First,
the evidence presented within this dissertation suggests that signaling through ER is in fact
sufficient to upregulate ALPP expression. Evidence presented within Chapter III utilized
conventional Ishikawa cells and highly-specific ER agonists in combination with the ER
inhibitor ICI 182780. These studies revealed that ER, not ER, was responsible for
upregulation of ALPP message and enzymatic activity. Furthermore, data gathered utilizing
3H12 cells expressing ER or ER confirmed that ER is the receptor responsible for
inducing ALPP message and enzymatic activity.
The second explanation which may explain the “weak” induction of ALPP by estrogen is
the notion that the parental Ishikawa-3H12 cell line lacks other required factors. This may
provide a better explanation as to why the Ishikawa-3H12 cells “weakly” induce ALPP
activity and message when compared against conventional Ishikawa cells. The current
literature suggests the Ishikawa-3H12 cell-line not only lacks functional expression of the
ERs, but also lacks expression of both progesterone receptor (PR) subtypes (Hanekamp et al.
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2003; Nishida 2002; Nishida et al. 1996). Therefore, it is reasonable to propose that key
components involved in the normal upregulation of the ALPP gene may also be absent from
the Ishikawa-3H12 cells.
The third and final explanation with regard to the “weak” induction of ALPP in Ishikawa-
3H12 cells as compared against conventional Ishikawa cells could come from differences in
the subcellular localization of the ERs. Data presented within Chapter IV of this dissertation
suggests that membrane and/or cytoplasmic versions of ER have an important role in the
induction of ALPP message and activity. Therefore, the 3H12 cells may not have the same
number of membrane/cytoplasmic receptors as the conventional Ishikawa cells. This final
point was not evaluated within this dissertation and needs to be addressed by
immunofluorescence or Western immunoblot of proteins from cellular fractions.
Specific Aim III. Characterize the Roles of the Estrogen Receptors  and  on Cellular
Proliferation in Human Ishikawa Endometrial Epithelial Cells.
Much of the work in the literature evaluating the roles of the estrogen receptors in human
endometrial epithelial cells has implicated redundant roles for these receptors. Many of these
studies utilized small interfering RNA (siRNA) to reduce the expression of one receptor,
while attempting to study the biology of the second (Ali et al. 2000; Taylor et al. 2002;
Zhang et al. 2006). The downfall with this approach is that cells maintain partial expression
of the target receptor, which may contribute to the observed results. Additionally, separate
studies have transiently overexpressed the ERs to study their biology. Unfortunately,
overexpression studies suffer from problems analogous to those of experiments with the use
of siRNA. The work presented in this dissertation using cells that express only one receptor
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at a time allows for the elucidation of individual roles and provides evidence supporting the
hypothesis that the ERs have distinct and divergent influences on the proliferation of human
endometrial adenocarcinoma cells.
With the use of specific agonists of the estrogen receptors and cell lines that express
either receptor subtype alone, we have been able to elucidate the roles of the estrogen
receptors on proliferation of Ishikawa endometrial epithelial cells. First, we have shown that
the ER is the primary receptor involved in increased proliferation induced by 17-estradiol.
In the case of the ER agonist PPT, we observed an increase in proliferation at
concentrations equivalent to those physiologic for 17-estradiol, 10-8M. Further studies using
3H12 cells revealed that introduction of ER leading to its expression in these cells could
restore the ability of the cells to produce a significant response to 17-estradiol. Further
studies evaluating the role of ER in proliferation showed that treatment of conventional
Ishikawa cells with 10-8M DPN produced no significant change in proliferation. However,
when cells expressing ER only (3H12) were used, we observed that this receptor had an
inhibitory effect on proliferation and cell cycle progression, even in the absence of 17-
estradiol treatment. The creation of new cell lines which express ER, ER, or both have
shown that the ERs possess different roles in the context of proliferation of the Ishikawa
adenocarcinoma cells. This finding conflicts with previous reports in human endometrial
cells, but parallels findings in human breast MCF-7 and T47D adenocarcinoma cells.
(Hartman et al. 2006; Paruthiyil et al. 2004; Strom et al. 2004).
We recognize that the model system created for this dissertation may not completely
reflect the normal biology of human endometrial epithelial cells. First, the use of a well-
differentiated human endometrial adenocarcinoma cell line may not accurately reflect the ER
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biology in normal human endometrial epithelial cells. However, we were limited to the use of
abnormal cell lines because normal endometrial epithelial cell lines were not available at the
beginning of this dissertation. Within the past few months a normal epithelial cell line,
hTERT-Endometrial Epithelial Cells, has been made available to our laboratory. Although,
the normal endometrial epithelial cell line expressing both ERs has been identified, it could
not be used for studies expressing only one estrogen receptor at a time. Furthermore,
isolating a normal cell line that lacks expression of the ERs would be virtually impossible, as
the lack of one or both ERs would lead one to believe that the cells were abnormal.
Additionally, studies contained in this dissertation did not utilize co-culture systems,
which would approximate better the normal biology of the uterus. However, the goal of this
dissertation was to study the effects of 17-estradiol, as opposed to paracrine mediated
factors emanating from the stroma, on epithelial cells. Therefore, the use of the co-culture
model system in this dissertation would not permit the elucidation of the roles of the estrogen
receptors within our target cells. Because of our efforts and techniques this dissertation has
yielded novel observations which will further our understanding of ER biology within
epithelial cells of the human endometrium.
Stable reconstitution of the ER or ER into 3H12 cells has provided an excellent model
system for the elucidation of the roles of the receptor subtypes in endometrial
adenocarcinoma cells. Figures 4.4 and 4.5 reveal the effects of both ER and ER,
respectively, on proliferation of endometrial adenocarcinoma cells. In both figures, we
observe significant changes in proliferation in the absence of 17-estradiol. That is,
reconstitution of ER significantly increased proliferation, while introduction of ER
significantly decreased proliferation of the parental cell line. Throughout this dissertation I
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have presented a case that the activation of the ERs is an extremely dynamic and complex
process. With that in mind, there are several plausible explanations that may shed light on the
underlying mechanisms by which the effects of the ERs are elicited in the absence of added
estradiol in this model system. First, despite our efforts to remove all steroid hormones from
the medium, via charcoal-stripping the fetal bovine serum, trace amounts of steroids may
remain and activate the ERs through the classic pathway. Second, the ERs are
phosphoproteins which can be stimulated/activated by various cytoplasmic signaling
pathways, including (PI)3-Kinase and MAP-Kinase (Campbell et al. 2001; Kato et al. 1995;
Kato et al. 2000). Many cytoplasmic signaling pathways have been shown to be stimulated
by various growth factors, which may be contained within the tissue culture medium used for
these studies. Therefore, it is plausible to postulate that activation of the receptors by the non-
classic pathway may explain the observations with regard to significant changes in
proliferation of the 3H12 cells in the absence of 17-estradiol.
The Experimental Rigor with which the Hypothesis was Addressed
Our hypothesis was that ER acts as a modulator of ER signaling in the human
endometrium. We have tested this hypothesis in three series of experiments. First, we used
immunohistochemistry to observe an alteration of the normal ER/ER ratio in premalignant
endometrial tissues. Prior to embarking on these studies we consulted with a biostatistian to
determine the number of patient samples needed to achieve 95% power within our studies.
To avoid observer bias in interpreting images, scorers were provided with digital images of
tissue cores to be scored semi-quantitatively with only a coded study number to distinguish
them. We elucidated the roles of the receptor subtypes on the estrogen-inducible alkaline
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phosphatase gene expression and cellular proliferation of Ishikawa human endometrial
epithelial cells, using commercially available highly specific agonists of the estrogen
receptors. The activity of the two receptors was also evaluated using cell lines that express
only one receptor subtype. Each experiment included within this dissertation was repeated at
least three times and the results herein are representative of each experimental data set.
Future Directions
The studies performed in preparation of this dissertation have been geared primarily
to elucidate the roles of the estrogen receptors  and  in the epithelial cells of the human
endometrium. There are numerous experiments that could be done to more completely
characterize the physiologic roles and molecular mechanisms of these receptors in this tissue.
The additional studies may be classified into several broad categories: 1) further characterize
the conditions that modify the ER/ER ratio in the human endometrium 2) characterize the
molecular effects of ER and ER on more classic estrogen-responsive genes, including
those known to contain EREs 3) further characterize the effects of ER and ER on cell
cycle progression in endometrial epithelial cells and 4) characterize the effects of the receptor
subtypes on paracrine mediators from the stromal compartment.
A list of possible approaches for the study of these questions follows.
1) Since the risk of developing endometrial cancer is associated with unopposed
estrogens and increased age, additional studies could evaluate the levels of the ERs in pre-,
peri-, and post-menopausal women. If our data suggesting an alteration in the ratio of ER to
ER is correct we might expect to see a change as women age. Information taken from this
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series of studies may further support our observations, and may be useful in developing
strategies to prevent malignant transformation of the endometrium.
2) Additional studies could determine if the alteration in the expression of ER and
ER occurs prior to the development of morphologic hyperplasia in the human endometrium.
A larger study could evaluate more independent stages of normal and diseased endometria
rather than grouping into normal, hyperplastic, and malignant samples as was done in this
study. We could include endometrial samples from the proliferative and secretory phases of
the menstrual cycle, endometria from women predisposed to hyperplasia (i.e. Polycystic
Ovarian Syndrome, Cowden’s syndrome, simple hyperplasia, complex hyperplasia, complex
hyperplasia with atypia, and endometrioid (Type-1) adenocarcinomas. Having more
categories to evaluate for changes in the ER/ER ratio could validate our current finding’s
and also determine how early in the course of adenocarcinoma development this ratio
changes.
3) We could examine the roles of the receptors on genes known to contain classic
EREs within their promoter to understand if the receptors continue to adhere to the overall
hypothesis regarding their independent roles. There are several genes in which extensive
characterization has been completed on the estrogen response elements contained within their
promoters. These genes include, but are not limited to, Capthesin D and Cyclin D1. The latter
is of great importance as it may play a critical role in the effects of the receptors on
progression through the cell cycle.
4) We observed that the two estrogen receptors have different roles in the regulation
of cell proliferation by our endometrial adenocarcinoma cells. This raises questions about
how the two receptors function in the stimulation and/or inhibition of cell cycle progression.
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To be better informed about this, we could evaluate the effects of each receptor on the
progression of the cell cycle in specific endometrial cells. We could use BrdU incorporation
and flow cytometry to determine the cell cycle profiles of the null and receptor expressing
cells. We could then complete a systematic evaluation of cell cycle proteins that are involved
in the inhibition or progression through the cycle including their expression and activation.
This information may give us insight about why 17-estradiol acting through ER increases
cellular proliferation above that in the receptor null parental cells, while 17-estradiol acting
through ER reduces proliferation of our cells.
5) It has recently been recognized that normal human endometrial epithelial cells do
not proliferate directly in response to estrogens in vivo. Rather, the stromal cells respond to
estrogens and releases paracrine mediators, which induce or repress cellular proliferation by
endometrial epithelial cells. Therefore, we could evaluate the effect of stable overexpression
of one receptor or the other in normal stromal cells to understand the independent roles of the
receptors in the release of paracrine factors by the stromal cells. The use co-culture models or
treating epithelial cells with media conditioned by stromal cells will allow us to test whether
the actions of estrogen through the two receptors in the endometrial cells demonstrates that
divergent functions of ER and ER mediated estrogen responses provides a consistent basis
for the observed features of endometrium in vivo.
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